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Triple negative breast cancer is one of the most aggressive breast cancer 
subtypes, for which there are no approved targeted therapies. In US alone, the 
incidence of TNBC is highest in women with African ancestry (AA); in western 
sub-Saharan Africa, single-institution studies show that TNBC constitutes 40- 
80% of all breast cancer cases. There is an urgent need to find actionable targets 
in TNBC of all ethnicities, but especially in patients with African ancestry, whose 
tumors are suspected to be more aggressive.  Here, we sought to better 
understand the biology of TNBC by finding genes and pathways that are 
differentially expressed in the stem cell population of patient derived xenografts 
(PDX) created with TNBC tumors from Ghanaian (GH), AA and White American 
(WA) women and the effect of these differentially expressed genes on the stem 
cell phenotype in these primary tumors. 
We first established an international, inter-institutional collaboration with a 
teaching hospital in Ghana (Komfo Anokye teaching hospital, KATH) for the 
acquisition of patients’ samples. From these samples, we created patient derived 
xenograft models that serve as a renewable source of tumor tissue to study the 
cancer biology. Breast cancer stem cells, the small population of cells that have 
been shown to mediate breast tumor initiation, metastasis, and resistance to 
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conventional therapy have also been reported to mediate the heterogeneity of 
TNBC and are especially abundant in TNBC in AA women. We therefore sought 
to understand the biology of these stem cells in our primary patient samples and 
their associated PDX models.  
We report here that, through our collaboration, we now have a better 
understanding of the diversity of the breast cancers that occur in Ghana and 
other parts of Africa, we have contributed to an improvement in the diagnosis and 
treatment of breast cancer patients and have contributed to enriching the human 
resource at the KATH in Ghana. We have successfully created a cohort of PDXs 
from TNBC patients in Ghana as well as African-American and White American 
patients. By sequencing the stem cells in these tumors, we have identified the 
aldehyde dehydrogenase (ALDH) expressing stem cell population to represent 
the stem cells in these aggressive tumors from this diverse population. We 
identified 14 genes that were simultaneously differentially expressed between the 
two-breast cancer stem cell sub-populations in (ALDH+ vs the CD44+/CD24-
/EPCAM+) as well as ALDH+ vs bulk (p-value <0.001, FDR < 0.05 for both 
comparisons). The 3 most significant genes were matrix metalloproteinase 2 
(MMP2) and Protocadherin 7 (PCDH7), both known to be involved in breast 
cancer metastasis and Probable carboxypeptidase X1 (CPXM1), a carboxylase. 
Inhibiting MMP2 expression in the PDX cells grown in suspension resulted in 
significant reduction in the ALDH+ cell population. Also, the ALDH+ and not the 
CD44+/CD24- cells formed spheres in serum free media. The WNT, MAPK and 
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TGF-beta pathways known to mediate metastasis were all significantly up-
regulated in the ALDH+ population with down regulation of biosynthetic pathways 
which were up-regulated in the CD44+/CD24- population. Further studies are 
ongoing on pathway modulation in ALDH1+ cells based on these findings. 
Together, these findings demonstrate the importance of international 
collaborations with mutual benefits. It also shows that TNBC, being a very 
heterogeneous disease, may be driven by a population of tumor cells that can be 
targeted to improve patient outcome. 
 1 
Chapter 1 : Introduction 
 
Breast Cancer Burden 
Breast cancer (BC) is the most common cancer diagnosed in women 
worldwide with an estimated 1.7 million new cases diagnosed in women 
worldwide in 20123. Globally, the burden of breast cancer exceeds all other 
cancers and the incidence is increasing. In 2015 there was an estimated 2.4 
million incident cases making it the most common cancer. It is the fifth leading 
cause of cancer deaths for both men and women.  For women, breast cancer 
was the leading cause of death in 2015.4 
In the united states, approximately one in eight women (12%) will develop 
invasive breast cancer over the course of her lifetime. In 2016, it was estimated 
that, more than 3.5 million women living in the United States have a history of 
invasive breast cancer, an additional 246 660 new cases of invasive breast 
cancer are expected to be diagnosed and approximately 40450 would die as a 
result of it 5. The median age at diagnosis of breast cancer is much younger than 
other common cancers. It is 61 years for breast cancer compared with 70 years 
for lung cancer and 68 years for colorectal cancer with About 19% of breast 
cancers diagnosed in women ages 30 to 49 years5 4. There is therefore more 
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room for continuous research in breast cancer aiming at improving patient 
outcome. 
  
Breast Cancer Incidence and Mortality  
Globally, the incidence rates for breast cancer varies nearly four-fold 
across the world regions, with rates ranging from 27 per 100,000 in Middle Africa 
and Eastern Asia to 92 in Northern America. Higher breast cancer incidence in 
more developed countries is mostly attributed to the routine mammographic 
screening which helps in early detection of breast cancers 6. Other non-
hereditary factors more prevalent in western countries and are known to increase 
the incidence of breast cancer include weight gain after age 18 years, excess 
body weight (for postmenopausal breast cancer), use of menopausal hormone 
therapy, physical inactivity, alcohol consumption, and reproductive and hormonal 
factors, such as a long menstrual history, over use of oral contraceptives, and 
nulliparity or later age at first birth 7. the incidence in the more developed parts of 
the world in now considered stable 7. Breastfeeding may decrease the risk of 
some subtypes of breast cancer. In contrast, breast cancer incidence rates in 
many other countries, especially low to middle income countries (LMICs), 
continue to increase. The causes of these increases are not completely 
understood, but are thought to include changes in reproductive pattern as well as 
increased awareness and screening6. 
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Although the incidence rate is higher in the western more developed 
countries (92 per 100000 in North America) compared to developing countries 
(27 per 100000 in middle Africa), the mortality rate is far higher in the developing 
world (20 in 100000 in western Africa) compared to the western world (6 per 
100000 in Eastern Asia)3, Figure 1.1.  This global disparity in breast cancer 
outcome can mainly be attributed to factors such as lower life expectancy as well 
as low socioeconomic status in the developing world that leads to lack of 
screening modalities, delayed diagnosis and inadequate treatment among 
others. In a study by Ward et al, it was demonstrated that the poorest 
communities in any ethnic group had the worst prognosis in any cancer, stating 
the fact that poor socioeconomic status (SES) is an adverse prognostic factor in 
cancer outcome irrespective of Ethnicity8. 
Low SES however, is not necessarily the only determinant of BC ethnicity-
related outcome disparity as it does not explain for biological features such as 
high prevalence of aggressive BC subtypes, younger age distribution and higher 
 4 
incidence of male breast cancer in western Africa for example1,9-11. 
  
 
In a large (13,000 African American (AA) and 70,000 white Americans 
WA)) met-analysis conducted by Newman and coworkers in the USA reporting 
 
Figure 1-1: GLOBOAN 2012 global breast cancer incidence to mortality ratio 
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on the survival of AA and WA breast cancer, they adjusted for SES, age and 
stage of diagnosis and showed that AA background was associated with a 
mortality hazard ratio of 1.27 (95% CI 1.18-1.38)12,13. This can be explained in 
part by the high incidence of an aggressive breast cancer subtype that lacks 
targeted therapy, in AA women as compared to WA women. 
 6 
 
In the United States, during 2008 through 2012 (the most recent 5 years of 
data available), overall breast cancer incidence rates increased among black 
women (0.4% per year) but did not change significantly among white women. 
Breast cancer incidence rates for whites and blacks converged in 2012, reflecting 
 
Figure 1-2 : Trends in Female Breast Cancer Incidence and Mortality Rates by 
Race/Ethnicity, United States, 1975 to 20121 
Rates are per 100,000 females, age adjusted to the 2000 US standard population, 
and incidence rates are adjusted for reporting delay. †Rates are 3-year moving 
averages. NH indicates non-Hispanic; API, Asian/Pacific Islander; AI/AN, American 
Indian/Alaska Native. Sources: Incidence: Surveillance, Epidemiology, and End 
Results program, National Cancer Institute, 2015. Mortality: National Center for 
Health Statistics, Centers for Disease Control and Prevention, as provided by the 
Surveillance, Epidemiology, and End Results program, National Cancer Institute, 
2015. For Hispanics, incidence data do not include cases from the Alaska Native 
Registry and mortality data exclude New Hampshire and Oklahoma. Data for 
American Indians/Alaska Natives are based on Contract Health Service Delivery 
Area (CHSDA) counties.1 
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the increased incidence in black women and relatively stable rates in white 
women, figure 1-2.  
  
Figure 1-3: Female breast incidence trends, select countries, 1973–2012 
  (Compiled from: US, Surveillance, Epidemiology, and End Results [SEER] 
Program, 9 registries, 1973–2012; Denmark, Norway, Sweden, 2008–2012 




A striking divergence in long-term breast cancer mortality trends between black 
and white women emerged in the early 1980s and has since continued to widen, 
(figure 1-2); and, by 2012, mortality rates were 42% higher in black women than 
in white women. Trends in breast cancer mortality rates by race/ethnicity are also 
shown in figure 1-3. From 2003 through 2012, breast cancer mortality rates 
declined annually by 1.8% in whites and only 1.4% in blacks1. Several studies 
indicate that the difference in breast cancer mortality are likely due to a 
combination of factors, including differences in incidence rates (at least during 
the recent time period), stage at diagnosis, obesity, comorbidities access, 
adherence, and response to state-of-the art treatments and a difference in tumor 
biology1,14,15. Treatment of breast cancer is stratified based on the sub-type of the 
tumor. 
 
Breast Cancer Sub-types 
Breast cancer is a heterogeneous disease with a high degree of diversity 
within a tumor. The heterogeneity of breast cancer makes it a challenging solid 
tumor to diagnose and treat. Historically, many factors have been investigated as 
a means to stratify patients, to prognosticate and to decide on treatment options. 
These include age, parity and family history among others. However, tumor 
receptor status has provided the most useful information in predicting prognosis 
and responsiveness to treatment. Using Immunohistochemistry, the expression 
of estrogen receptor (ER), progesterone receptor (PR), and overexpression of 
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human epidermal growth factor receptor 2 (HER2/neu) is measured16-18. Breast 
cancers are classified with respect to the presence or absence of these 
receptors. Patients whose breast tumors express estrogen receptor are classified 
as ER-positive (ER+) and breast tumor which do not express ER are classified as 
ER-negative disease with approximately 70% of breast cancer patients having 
ER+ disease. When ER is present, it drives cancer growth and is a therapeutic 
target and these patients are treated with endocrine therapy19 which aims at 
either reducing the estrogen receptor activity or reduce receptor levels within 
breast cancer cells. Overexpression of the Human epidermal growth factor 
receptor 2 (HER2/neu) classifies breast cancer as HER2 positive breast cancer. 
Persistent activation of signaling pathways as a result of amplification of the 
human epidermal growth factor receptor 2 (HER2) in patients with HER2-positive 
breast cancer leads to a biologically aggressive malignancy with heightened 
sensitivity to cytotoxic chemotherapy20. In these patients, the addition of HER2 
targeted therapy (trastuzumab and pertuzumab) both in the neoadjuvant and 
adjuvant setting, significantly improves the patient outcome21. TNBCs, classified 
based on the absence and not the presence of receptors, thus cannot be treated 
with any of these targed therapies. Amongst individual breast cancer subtypes, 
those classified as triple negative breast cancers (TNBCs) are especially 
lethal due to their high metastatic potential and h i g h  propensity to recur. As a 
group, TNBCs lack expression of hormone receptors (ER-a and PR) and lack 
overexpression of human epidermal growth factor receptor 2 (ErbB2/HER2). 
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Thus, therapies directed against these robust targets are not effective against 
TNBC. TNBC is the only subset of breast cancers for which there are no FDA-
approved targeted therapies and clinicians are entirely reliant upon cytotoxic 
agents for tumor control. Clearly, there is a significant need for targeted 
therapeutics against TNBC. 
 
Triple Negative Breast Cancer 
Triple negative breast cancer (TNBC) is the subtype of breast cancer with the 
worst prognosis and is defined by having less than one per cent expression of 
the estrogen and progesterone receptor,17 and no overexpression of the HER2 
oncogene; either 0, 1+ by immunohistochemistry or 2+ with fluorescence in situ 
hybridization negative18,22. 
Triple-negative breast cancer accounts for approximately 20 percent of breast 
cancers diagnosed worldwide, which amounts to almost 200,000 cases each 
year23. Triple-negative breast cancer is more commonly diagnosed in women 
younger than 40 years compared with hormone-positive breast cancer. In one 
study, there was a twofold higher attributable risk of triple-negative breast cancer 
in women under 40 years compared with women over 50 years (odds ratio [OR] 
2.13, 95% CI 1.34-3.39) 23 
 Using gene expression profiling, about 80% of TNBC cases belong to the basal 
BC subtype which is biologically very aggressive24,25. By definition, patients with 
TNBC cannot be treated with endocrine therapy, nor with anti-HER2 proto-
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oncogene targets since the tumor is defined by the absence and not the 
presence of these targets.  TNBC has a 5-year overall survival of 64% vs. 81% in 
non-TNBC, it has the highest rate of visceral and distant relapse, and the 
shortest survival after the development of metastasis26-28. As there are no 
approved targeted therapies for TNBC, chemotherapy is the mainstay of 
systemic treatment in either the neoadjuvant setting or after loco-regional therapy 
with surgery and radiotherapy 22,29. Patients with TNBC have a higher rate of 
complete pathological response after neoadjuvant chemotherapy (22% v 11%; P 
= .034) as compared to non-TNBC, which correlates with a better prognosis in 
TNBC27,30. Eight out of ten of TNBC patients have residual disease and they are 
at an increased risk of relapse and metastasis26,28 with a higher rate of brain 
metastasis as compared to non-TNBC25. The unique molecular complexity and 
extremely heterogeneity of the TNBC has attracted a lot of research efforts to 
define molecular targets. Several attempts have been made to classify TNBC 
into subtypes, with the aim of describing prognostic categories31-34; however, 
these sub-classifications are yet to translate into direct clinical benefit.  
In the United states, 15% of all breast cancers are TNBC, in contrast, the 
Carolina BC study reported that 39% 35of all invasive breast tumors diagnosed in 
premenopausal AA women were TNBC, highlighting the potential the potential 
role of TNBC in BC cancer outcome disparity. Several other studies have 
reported that the population based incidence of TNBC in AA in twice that of WA 
in all age categories. This includes the 2015 “Annual Report to the Nation on the 
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Status of Cancer” which cited a 27.2 vs 14.4 per 100 000 women respectively 36-
38. The TNBC phenotype is associated with an increased in hereditary 
susceptibility to BC irrespective of family history39. The AA population of the USA 
constitutes a genetic admixture of several ancestral populations with their African 
ancestry originating largely from Western Africa through forced migration from 
the trans-Atlantic slave trade40. It is therefore worthy of note that the incidence of 
TNBC in west African women has been reported to be as high as 80% of all 
breast cancer diagnoses in several institutional based studies. While African 
American women have a higher incidence of TNBC than European American 
women in the USA, West African women with pure African ancestry have a much 
higher incidence. The average incidence is 10 - 21%, 21 - 46%, and up to 82% 
for WA, AA and west Africans respectively35,41-45. The question begging to be 
asked therefore is, is African ancestry associated with a hereditary susceptibility 
to TNBC and can we better understand the biology of TNBC if we study the 
genetic makeup of these tumors in women with African ancestry. Considering the 
fact that the African continent is the oldest continent and being the origin of all 
other ethnicities, we might find gene and pathways signaling in the African 
tumors. 
 
Hereditary Breast Cancer and Breast Cancer in Blacks  
Approximately 10% of all breast cancers are hereditary46. Hereditary breast 
cancers are autosomal dominant in transmission and occur at an earlier age. 
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Defects in the BRCA1 and BRCA2 genes accounts for most cases of hereditary 
breast cancer with several additional mutations now being associated with an 
increased risk of developing breast cancer46. The BRCA1 and BRCA2 genes, are 
tumor suppressor genes that were discovered in the mid-1990s47,48. A woman 
who carries a BRCA1 mutation has a 57% lifetime risk of developing breast 
cancer, whereas a woman with a BRCA2 mutation has a 49% risk49,50. Once a 
woman is diagnosed with breast cancer, if she is a carrier of a BRCA1 or BRCA2 
mutation, she has an increased risk of developing a second breast cancer in the 
contralateral breast. 
Up to 20 percent of patients with triple-negative breast cancer harbor a breast 
cancer gene (BRCA1/2) mutation (Even among patients unselected for family 
history of breast cancer), particularly in BRCA151. By contrast, less than 6 
percent of all breast cancers are associated with a BRCA mutation. Population-
based studies have reported that Black women are approximately two to three 
times more likely to have triple-negative breast cancer (TNBC) than White 
women37,52. There is limited data on the prevalence of deleterious BRCA1 and 
BRCA2 (BRCA1/2) in blacks with most of the available data arising from 
population-based studies or from cohorts comprising highly selected families53. In 
individuals referred for genetic testing, the prevalence of BRCA1/2 mutation in 
women of African ancestry ranged from 12.1 to 15.6 % and were significantly 
higher than in women of Western European ancestry (ranged from 7.5 to 
12.1 %). In western sub-Saharan Africa, where there is the highest reported 
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prevalence of TNBC, almost, nothing is known of the prevalence of BRCA gene 
mutations in TNBC patients. Given the high rate of early onset breast cancer and 
TNBC in Black women, it is important to determine the prevalence of BRCA1/2 
mutations in this population54 
 
Breast Cancer Treatment 
When breast cancer is detected early without detectable distant metastases is a 
considered a potentially curable disease.  After diagnosis, therapy concepts are 
usually decided by a multidisciplinary team. The therapeutic option for each 
patient is determined based on the results of clinical examination and breast 
imaging (mammography, breast ultrasound), after a tissue diagnosis of 
malignancy has been established. In patients with early-stage-breast cancer, 
surgical options include breast-conserving therapy (breast-conserving surgery 
plus radiation therapy [RT]) or mastectomy (with or without RT). In patients with 
locally advanced inoperable breast cancer, neoadjuvant systemic therapy 
(chemotherapy usually) is instituted. These patients are usually not candidates 
for breast conservation at their initial presentation. Neoadjuvant treatment 
improves the rate of breast conservation without compromising survival 
outcomes. Following surgery, patients may receive adjuvant radiation therapy to 
maximize loco regional control55. Patients with HER2-positive breast cancer 
receive one year of trastuzumab following completion of surgery55-59. Patients 
with hormone receptor-positive breast cancer receive adjuvant endocrine 
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therapy. Patients with hormone receptor-negative breast cancer receive no 
further treatment provided they completed the planned neoadjuvant 
chemotherapy regimen. These patients then begin post-treatment surveillance. 
By exploring new approaches and finding vulnerabilities in TNBC, it might be 
possible to find targeted therapies for these patients in the adjuvant setting. One 
such approach is studying the cancer stem cells that have been shown to 
mediate tumor metastasis. 
 
Cancer Stem Cells 
Recent data suggest that cancer cells are heterogeneous and that only a small 
and discrete subset possesses self-renewal capacity. This particular 
subpopulation is thought to be responsible for sustenance of tumor growth and 
recurrence, termed “cancer stem cells” (CSCs)60-63. The cancer stem cell model 
proposes that the cells in a tumor are organized in a hierarchical manner with the 
stem cell sitting at the top of the hierarchy. The stem cell has the potential of self-
renewal as well as the ability to differentiate into all the other cells that makes up 
the bulk tumor64,65.  For successful control of tumor growth, it has been proposed 
that these cancer stem cells must be eradicated. Dick and colleagues pioneered 
this field in 1997 and demonstrated that only cells with a CD34+/CD38- 
phenotype were able to initiate human acute myelogenous leukemia (AML) in 
non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice60. 
These cells were capable of self-renewal and recapitulation of the leukemia 
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similar to the parental tumor phenotype in vivo.   Furthermore, leukemic stem 
cells are not functionally homogeneous but consist of a distinct hierarchically 
arranged class similar to normal hematopoietic stem cells60. In breast cancer, Al-
Hajj and colleagues were the first who identified breast CSC phenotype. They 
demonstrated that as few as 100 cells with a CD44+CD24-/low lineage- 
phenotype isolated from human breast tumors and malignant pleural effusion can 
initiate breast cancer in NOD/SCID mice reflecting the self-renewal capability of 
this phenotype. In contrast, injection of tens of thousands of cells with different 
phenotypes failed to form any tumors61. Further study showed that although the 
CD44+CD24-/low lineage- population accounts for only less than 10% in the 
primary tumors, the majority (71%) of the disseminated breast cancer cells 
detected in bone marrow exhibit this breast CSC phenotype, highlighting its 
significant role in future relapse and distant metastasis61. Moreover, there is a 
direct correlation between the prevalence of this phenotype in the primary tumor 
and the risk for distant metastasis66-68. Several groups demonstrated that self-
renewal pathways as well as multiple “stemness” genes are highly expressed in 
CD44+CD24-/low breast cancer cells. These include hedgehog signaling 
components such as PTCH1, Gli1, Gli2, and the polycomb gene Bmi-169,70.  
Aldehyde dehydrogenase (ALDH) is a family of enzymes important in the 
oxidation of alcohol and vitamin A as well as in resistance to 
cyclophosphamide71.  The human aldehyde dehydrogenase (ALDH) superfamily 
currently consists of 19 known putatively functional genes in 11 families and 4 
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subfamilies with distinct chromosomal locations72-74. Of the vast ALDH families and 
subfamilies, it has been shown that the ALDH enzymes that are involved in normal stem 
cells as well as cancer stem cells (CSCs) include the ALDH1, ALDH3A1, ALDH4A1, and 
ALDH7A172. Cytosolic ALDH1 is highly expressed in human and murine 
hematopoietic stem and progenitor cells75.76  More recently, Ginestier and 
colleagues77 have demonstrated that both normal and breast cancer cells with 
higher ALDH1 expression have stem/progenitor properties. These cells with a 
higher ALDH expression level have the highest tumorigenicity in 
xenotransplantation and the most extensive lineage differentiation potential. High 
ALDH activity in breast cancer also distinguishes the tumorigenic cell fraction that 
is capable of self-renew and recapitulating the heterogeneity of the original 
tumor. Furthermore, expression of ALDH1 detecting by immunohistochemically 
(IHC) staining is found to be an independent predictive marker of poor 
prognosis78. 
 
Breast Cancer Stem Cells 
There is now an abundance of evidence supporting the existence of a small sub-
population of breast tumor cells with self-renewing potential, termed breast 
cancer stem cells (BCSC) or tumor initiating cells, that plays a major role in tumor 
recurrence and metastasis79,80. The existence of stem cells has been 
demonstrated in different tumors including leukemia60, breast61, colon81 and 
prostate82 among others. In these various studies, the stem cells were enriched 
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for by the expression of protein markers or the presence of the enzyme aldehyde 
dehydrogenase (ALDH) in the cell. In breast cancer, these stem cells can be 
isolated from the tumor mass using fluorescent activated cell sorting (FACS) 
when they are CD44+/CD24-/EPCAM+61,83. Furthermore, using the ALDEFLUOR 
assay, stem-like cells can also be isolated by measuring the activity of the 
intracellular aldehyde dehydrogenase enzyme in intact breast cancer cells77 
These cells have also been shown to be especially abundant in TNBC77 84,85, are 
responsible for resistance to chemotherapy and radiotherapy,86-88 and contribute 
to the heterogeneity observed in TNBC 89. ALDH+ BCSC have been shown to 
mediate metastasis and poor clinical outcome in breast cancer90. While the 
existence of phenotypic BCSC is supported by a large body of preclinical and 
clinical evidence, the pathways that contribute to the maintenance of this cell 
population are not clearly defined91 
 
Breast Cancer Ctem cells and Breast Cancer in Blacks 
The expression of ALDH1, the protein associated with the ALDEFLUOR 
activity, has been associated with TNBC and aggressive breast cancers in 
African women85. In our previous work, we showed that, a significantly high 
expression of ALDH1 in breast lesions (benign and malignant) of Ghanaian 
women. We also showed a higher expression of ALDH1 in TNBC as compared to 
other breast cancer subtypes84in these women. We have therefore hypothesized 
that the key to unraveling the complexity of TNBC and thus finding new targets 
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for its treatment lies in understanding signaling integrations and gene expression 
in the BCSCs of TNBC in women with African ancestry in comparison with other 
ethnicities. 
 
Implications of CSCs for Cancer Therapy 
Although most cancer patients may respond to therapy, an initial response is 
rarely translated into long-term survival. This is comparable to cutting a dandelion 
off at ground level. Although this will remove the visible portion of the weed, the 
hidden root remains underground and will eventually regrow. In order to entirely 
eradicate the weed, the unseen root also needs to be eliminated to prevent 
regrowth (“the dandelion phenomenon”)92. Most conventional chemotherapies 
mainly affect differentiated cancer cells that  make  up  the  bulk  of  a  tumor,  
but  are  often  ineffective  against  CSCs92. There are several mechanisms for 
chemotherapy resistance in CSCs. Similar to normal stem cells, CSCs are 
usually in quiescent G0 phase and enter cell cycling only when they receive 
proper signals from their niches. Therefore, CSCs are insensitive to S-phase 
specific chemotherapies. 
CSCs have a particularly efficient drug efflux pump systems compared to non-
CSCs. Hirschmann-Jax et al93. Identified ABC transporters as the means by 
which side population (SP) have an increased capability to efflux chemotoxic 
drugs in various tumor cells. SP have been shown to overlap in breast cancer 
with CD44+/CD24−CSCs94 in breast cancer. CSCs are hypothesized to have 
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higher radio resistance, by a superior DNA damage repair than non-CSCs akin to 
normal stem cells95.  In a recent study by Bao et al96. Radiotherapy was shown to 
enrich CD133+ glioma CSCs two- to four-fold, and these enriched cells had lower 
rates of apoptosis and higher activation of DNA damage repair (i.e. ATM, Rad17, 
Chk1, and Chk2).  Cancer stem cells have also been shown to have lower levels 
of reactive oxygen species (ROS) than the non-cancer stem cells96. 
Moreover, CSCs express high level of anti-apoptotic proteins, particularly 
members of the Bcl-2 family97, and drug transporters, such   as   ABCG2   
(BCRP)   and   P-glycoprotein. 98,99 The current challenge in anti-cancer drug 
development is therefore to find strategies to selectively target and eradicate 
CSCs. Perhaps, CSC directed   therapies   should   be   administered   in   
conjunction   with conventional debulking methods like surgery, chemotherapy, 
and radiation. It is also important to find the right model for studying breast 
cancer stem cells as it represents a sub-population of the cancer cells. 
   
Models for Breast Cancer Research 
The most widely used model for pre-clinical breast cancer research in vitro 
culture of established breast cancer cell lines. The use of these cell lines has 
many technical advantages; the complete of environmental conditions and 
standardized culture conditions ensuring the reproducibility of results between 
experiments and laboratories. It is cheaper than animal experiments and the use 
of these cell lines are almost infinite. It is however very limited. Although the cell 
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is cryopreserved, they undergo dedifferentiation resulting from multiple 
subcultures, leading to loss of special characteristics. The simplicity of cell 
cultures implies difficulties in extrapolating results to human tumors. They turn be 
less heterogeneous than human tumors and they lack stroma100. By contrast, 
Patient derived xenograft (PDX) tumors that are created when cancerous tissue 
from a patient’s primary tumor is implanted directly into an immunodeficient 
mouse have been shown to conserve the gene expression, histology, and 
architecture and heterogeneity of the original primary tumor from which they are 
developed. They turn to be more expensive and labor intensive but are more 
similar to the human tumor101-103. 
Most of the available data on the biology of TNBC was generated using 
cell lines developed mainly from white patient tumors, which do not serve as a 
true representation of the heterogeneous nature of TNBC.  They also utilize only 
the bulk tumor cells instead of the BCSCs, which are responsible for the 
increased rate of metastasis. In this study, we used a unique approach to finding 
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Women with African ancestry in western, sub-Saharan Africa and in the 
United States represent a population subset facing an increased risk of being 
diagnosed with biologically-aggressive phenotypes of breast cancer that are 
negative for the estrogen receptor, the progesterone receptor, and the HER2/neu 
marker. These tumors are commonly referred to as triple negative breast cancer. 
Disparities in breast cancer incidence and outcome related to racial/ethnic 
identity motivated the establishment of a breast cancer research partnership 
between the Komfo Anokye Teaching Hospital in Kumasi, Ghana and the 
University of Michigan Comprehensive Cancer Center in Ann Arbor, Michigan, 
and the Henry Ford Health System (HFHS) in Detroit, Michigan. This research 
collaborative has featured educational training programs as well as scientific 
investigations related to the comparative biology of breast cancer in Ghanaian 
African, African American, and White American patients. Currently, this 
International Breast Registry has expanded to include African American patients 
throughout the United States by partnering with the Sisters Network, Inc. (the 
only network for black breast cancer survivors in the united states); additional 
 34 
sites in Ghana (representing west Africa) as well as Ethiopia (representing east 




Financial constraints are a constant reality in low-and middle-income 
countries, and pose enormous barriers to both quantifying and addressing the 
cancer burden in sub-Saharan Africa. The limited data available have been 
generated by the Globocan 2008 database of the International Agency for 
Research on Cancer (IARC) and from recent attempts to report population-based 
cancer incidence rates from selected countries such as Uganda and Ghana 1-6. 
Taken together, these resources suggest that breast cancer is an increasing 
problem, and the likely explanations for this expanding health threat include more 
prolonged longevity in many African communities (as healthcare access 
improves, and with breast cancer risk increasing as women age); adoption of 
westernized, higher-fat dietary patterns (which can increase breast cancer risk in 
both pre- and postmenopausal women); and increased utilization of reproductive 
patterns that are more prevalent in western populations (such as delayed 
childbearing and reduced overall parity, which increased risk of hormone-
sensitive breast cancer). Rising rates of breast cancer cases are particularly 
alarming within sub-Saharan African countries, where the already-overburdened 
healthcare system is ill-prepared to afford early detection and multidisciplinary 
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treatment programs. The disturbing and excessively high mortality-to-incidence 
ratio of breast cancer in sub-Saharan Africa compared to other parts of the world 
are depicted in Figure 1. 
In the United States, race/ethnicity-associated disparities in breast cancer 
incidence and outcome have been documented for many decades. Breast cancer 
mortality rates are disproportionately higher for African American compared to 
White/European women, and African American women tend to be diagnosed with 
breast cancer at younger ages.  
 
Figure 2-1: International variation in breast cancer incidence, mortality, and 
mortality-incidence ratios. Data from Jamal et al7, Globocan 20088, Newman et al 9 
and Jiagge et al10. 
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The mortality differences have historically been ascribed to socioeconomic 
differences, since poverty rates and inadequate health care are more prevalent  
among African Americans. The younger age distribution for breast cancer, 
studies documenting higher mortality risk after adjusting for socioeconomic 
status, and advancing insights regarding the higher frequency of biologically 
aggressive tumors (such as triple negative breast cancer, TNBC) within the 
African American community have fueled speculation that African ancestry itself 
might be associated with hereditary susceptibility for specific patterns of breast 
cancer11-13. These issues provided the foundation for establishing the 
International Breast Registry (IBR), a breast cancer research partnership 
between the Komfo Anokye Teaching Hospital (KATH), the University of 
Michigan (UM), and the Henry Ford Health System (HFHS). This program is now 
being overseen by Dr. Sofia Merajver at the University of Michigan with our 
collaborators at the HFHS. Exploratory conversations and bi-continental 
introductory visits occurred in 2004-2005, and the institutional review boards of 
each institution provided their initial human research ethics approvals in 2006. 
The early goals of this collaborative were therefore related to studying the biology 
of breast cancer in women with African ancestry, and indeed the first joint 
publication from this team was a manuscript providing “how-to” guidelines for 
other investigators regarding the conduct of cancer research in developing/low- 
and middle-income countries.14 
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The IBR has grown enormously since its inception. While this collaborative 
continues to feature a robust breast tumor repository that has provided exciting 
data regarding breast cancer in Ghanaian African as well as African American 
women, it has also expanded its portfolio of educational and training exchange 
programs. In this review, we summarize the various outcomes of this 
international effort over the past ten years, as presented in peer-reviewed 
publications and academic meeting abstracts. We will also review the non-
research related productivity of this partnership, featuring investment in the 
oncology services infrastructure of Ghana. 
 
Breast Cancer and African Ancestry- Patterns identified through the IBR 
The concept of subtyping breast cancer has assumed increasing 
importance as our knowledge of targeted therapy has advanced. Invasive breast 
cancers that are positive for the estrogen receptor and/or the progesterone 
receptor can be managed systemically with a variety of endocrine agents- 
tamoxifen for premenopausal patients; and tamoxifen or one of the aromatase 
inhibitors for postmenopausal patients.  Tumors that overexpress HER2/neu 
benefit greatly from targeted, anti-HER2 therapy with trastuzamab and/or 
pertuzamab. Equally important and relevant to treatment planning is the fact that 
these targeted agents are contraindicated in cases that are negative for these 
markers, and utilizing them in cases that are negative for all three markers- 
tumors known as triple negative breast cancer (TNBC)- would result in exposing 
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patients unnecessarily to the toxicity of an ineffective regimen. Studies of breast 
cancer in the United States have revealed that frequency and population-based 
incidence rates of TNBC are significantly higher in African American women 
compared to women of other racial/ethnic identities 15,16. Speculation that African 
ancestry could be associated with inherited susceptibility for TNBC prompted 
comparisons of breast tumor phenotypes in African American and western, sub-
Saharan African women, as these two population subsets have shared ancestry 
resulting from the colonial-era slave trade13.  
One of the initial publications of the KATH-Michigan IBR collaborative 
therefore focused on comparisons of TNBC prevalence in White/Caucasian 
Americans compared to African American and Ghanaian women. The Henry 
Ford Health System (HFHS), which provides care to the robustly-diverse 
metropolitan Detroit Michigan community, served as the source for the 
comparison patient population. This study confirmed that TNBC accounted for 
the majority of KATH breast cancer patients17. Subsequent reports from this 
partnership, based upon larger sample sizes, have documented similar results. 
The most recent analyses, based upon immunohistochemistry studies of 234 
Ghanaian breast cancer patients (with complete marker profiling on 173 invasive 
tumors), reveal that 92 (53.2%) are triple-negative18. In contrast, the lowest 
frequency of TNBC was seen in WA patients (15.5%); and TNBC frequency for 
AA patients was intermediate between these two extremes at 30%. This pattern 
persisted in subset analysis of patients younger than 50 years. These findings 
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are consistent with the theory that extent of African ancestry correlates with 
likelihood of being diagnosed with TNBC, since AA patients represent a 
genetically admixed population.  
Table 2-1 summarizes the results of studies characterizing the breast 
cancer burden of Ghanaian women based upon data from the IBR research 
collaborative. While studies from the IBR have been enlightening with regard to 
understanding the breast cancer burden of western sub-Saharan Africa as 
exemplified by Ghanaian women, expansion of the registry has provided 
opportunities to study breast cancer in East Africa as well. Contributions from 
partners at the St. Paul’s Millennium Hospital in Addis Ababa have yielded 
interesting preliminary findings regarding breast tumor phenotypes from 
Ethiopian women. Immunohistochemistry performed at UM on 95 invasive breast 
cancers from Addis Ababa have revealed a low frequency of TNBC, at 9%19. In 
another study at the Merajver lab with colleagues from Ethiopia through the 
UMAPS program, we performed immunohistochemistry on 100 invasive breast 
tumors from Ethiopia and found the incidence of TNBC to be about 4%(waiting 
for results of FISH analysis, data not yet published). Patterns of the African 
diaspora and shared ancestry may explain these disparate results regarding the 
prevalence of TNBC in AA and Ghanaian women compared to Ethiopians. The 
colonial-era slave trade that was controlled by Europeans for the purpose of 
generating a labor supply in North America focused on capture and enforced 
trans-Atlantic transport of west Africans20. In contrast, enslavement of east 
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Africans from the region of Ethiopia was predominately perpetrated by Arab 
traders and enforced migration to northern Africa and Asia25,26. Fig 2-2 is shows 
the population migration patterns from different parts of Africa20. 
Table 2-1: Features of breast cancer in Ghana based upon studies from the Ghana-




 AA women are therefore more likely to have shared ancestry with women from 
western Africa, and this has been confirmed by genotyping studies of markers 
are associated with geographic ancestry, commonly referred-to as Ancestry 





Studies of breast tumor biology have generated the “stem cell” theory, 
which hypothesizes that mammary tumor virulence and metastatic risk is driven 
 
Figure 2-2:  Population migration patterns; the African diaspora; adapted from 
Campbell, et al20 
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by a small subset of cells within the cancer known as the stem cells. Efforts to 
identify and characterize the mammary stem cells therefore represent an exciting 
body of research. UM researchers have pioneered studies of the mammary stem 
cell hypothesis, and have reported on aldehyde dehydrogenase-1 (ALDH1) 
expression as a reliable, immunohistochemically-detectable marker of the 
mammary stem cell as well as being associated with more virulent tumors30. 
Studies of KATH tumors at UM demonstrated elevated expression of this marker 
in both benign and malignant breast tissue from Ghanaian women21.  
The polycomb group protein EZH2 is another molecule that has been 
implicated in mammary stem cell and TNBC progression, as demonstrated by 
UM researchers involved with the IBR31,32. We therefore incorporated studies of 
EZH2 into the IBR. This marker was found to have unique patterns of expression 
in Ghanaian breast specimens studied through the KATH-UM partnership23.  
Lastly, TNBC subtyping is a promising avenue for gaining insights 
regarding more refined, personalized treatment of TNBC33-37. Existing research 
suggests that there are at least six different TNBC subtypes, and some of the 
distinguishing features are related to luminal-like characteristics seen in the 
Androgen Receptor subtype versus the stem cell-like characteristics seen in the 
mesenchymal subtypes. Despite the disproportionately high frequency of TNBC 
among women with African ancestry, the TNBC subtyping research has been 
based almost exclusively on datasets representing White American, European, 
and Asian populations. No African datasets of gene expression profiles have 
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been available for inclusion in this body of research thus far. These issues 
motivated exploratory analyses of tissue from the IBR looking at expression of 
both androgen receptor and ALDH1 as immunohistochemistry surrogates for 
TNBC subtypes. Among the Ghanaian tumors, an intriguing finding appeared 
suggesting a novel TNBC subtype, featuring co-dominance of both androgen 
receptor and ALDH1 pathways38. 
As noted above, the partnerships within the IBR oncology teams has 
generated valuable insights regarding breast cancer phenotypes that are more 
prevalent among women with West African ancestry, such as triple negative 
tumors. Patient-derived xenografts (PDXs) represent an exciting research 
strategy for studying breast tumor biology and novel therapies. Implantation of 
breast cancer fragments into mice mammary fat pads yields a renewable supply 
of human tumors that can be used for a variety of in vivo rodent model 
experiments. Through the KATH-UM research partnership, a series of PDXs 
have been created based upon the tumors from Ghanaian; African American; 
and White American breast cancer patients.  
 
Breast Cancer in Ghana- Diagnostic and Treatment Advances Promoted by 
the Ghana-Michigan Partnership 
The IBR collaborative has also served as an investment in improving the 
clinical services available to Ghanaian women with breast problems. Historically, 
the KATH breast clinics relied predominantly upon open surgical diagnostic 
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biopsies in order to confirm or rule out the presence of cancer in any woman 
presenting with a breast abnormality or mass. The scheduling and 
implementation of a surgical diagnostic procedure is time-consuming and utilizes 
valuable, costly operating room resources. Furthermore, this sequence increases 
the risk that the affected patient (who has likely already travelled a distance and 
expended personal finances in order to seek medical attention) may be lost to 
follow-up. The early years of this partnership featured a training program in 
utilizing percutaneous core needle biopsies to diagnose breast cancer on-site 
during the outpatient clinic visit. The success of this program in terms of 
accurately and efficiently establishing a diagnosis of breast cancer has been 
reviewed and documented39.  
Multidisciplinary/multimodality treatment of breast cancer requires 
immunohistochemistry resources that can efficiently and accurately assess for 
expression of the estrogen receptor, the progesterone receptor, and HER2/neu. 
These markers are critical in being able to appropriately determine a patient’s 
response to endocrine therapy and/or targeted anti-HER2/neu therapy. Lacking 
this molecular marker information, hormone receptor-negative breast cancer 
patients may face the toxicity of ineffective endocrine therapy, and hormone 
receptor-positive breast cancer patients may miss the opportunity to receive life-
saving endocrine therapy. Similarly, HER2/neu expression can identify tumors 
that are quite sensitive to chemotherapy and anti-HER2/neu agents. The Ghana-
Michigan partnership featured a training program in immunohistochemistry for 
 46 
the KATH pathology team, as well as the development of a resource supply and 
allocation system that has enabled the KATH Breast Oncology Program to 
routinely generate their own molecular marker reports for each patient diagnosed 
with invasive breast cancer (Figure 2-2). 
This partnership has also generated opportunities to utilize telemedicine 
technology for real-time international collaboration and multidisciplinary 
discussion. The UM partners invested in dedicated internet and teleconference 
equipment on-site at KATH. This teleconference unit allows the UM and KATH 
teams to discuss patient care on a weekly basis and to share conference 
proceedings through live interactions. 
Our Ghanaian partners have also been able to promote general breast 
health awareness programs as a consequence of the expanded breast cancer 
attention generated by this research collaborative. KATH PI and manuscript co-
senior author B.A. has worked with regional herbalists, primary care physicians, 
and nurses to conduct educational seminars promoting breast cancer early 
detection strategies. Lacking adequate financial resources as well as accurate 
population-based statistics on breast cancer incidence, it is not feasible to 
conduct community-wide mammographic screening programs. These early 
detection programs therefore largely focus on dissemination of information 
regarding clinical signs and symptoms of breast cancer (dominant lump, bloody 
nipple discharge, etc.) and the importance of prompt biopsy with initiation of 
treatment. While we cannot quantify the effectiveness of our efforts with regard to 
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breast cancer stage distribution in Ghana, our KATH colleagues have 
established a tumor registry office (Kumasi Cancer Registry, Dr. Baffour Awuah, 
Director; unpublished data; personal communication) and have seen increasing 
volumes of breast cancer annually as well as anecdotal observations of more 
women presenting with operable, earlier-stage disease. Strengthening this 
Tumor Registry (which has struggled with consistent personnel and 
completeness of data collection) remains a high priority for the Michigan-Ghana 
Collaborative and we have also invested in advanced training of tumor registry 
personnel Although lumpectomy and breast radiation is an option that is available 
to breast cancer patients in Ghana, few women present with tumors that are 
amenable to the breast conservation approach despite anecdotal observations of 
an earlier stage distribution for KATH patients. Furthermore, concerns regarding 
inadequate pre- and postoperative mammographic imaging availability has 
generated suspicion that breast-conserving surgery cannot be planned with 
optimal information regarding extent of disease and adequacy of resection.” 
 
Breast Cancer and African Ancestry: The Ghana-Michigan Partnership as a 
Model for Expansion 
The multifaceted success of the Michigan partnership with the Komfo 
Anokye Teaching Hospital has established the foundation for expansion and 
collaboration with other healthcare facilities in Africa. As a consequence, this 
program has grown, with exchange programs that have included St. Paul’s 
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Millennium Hospital in Ethiopia as well as three additional sites in Ghana: the 
Korle Bu Teaching Hospital in Accra; the Tamale Teaching Hospital in Tamale; 
and the Sunyani Teaching Hospital in Sunyani. Table 2 summarizes the studies 
that have been published and presented through these partnerships. 
International expansion efforts beyond Africa are also in development, as 
partnerships evolve with the All India Institute of Medical Sciences in New Delhi 
and the Third Xiangya Hospital, Central South University. 
 
 




The KATH-UM relationship has served as a platform for training the 
physician-scientists from Ghana. More than a dozen Ghanaians have spent time 
at UM for observorships and research programs in the Merajver lab as well. E.J. 
is a surgeon from KATH, currently completing her PhD work at UM in Cancer 
Biology, after which she will return to Ghana to assume leadership of a Ghana-
based translational research program. 
Within the United States, expansion of this registry has involved 
partnership with the Sisters Network, Inc. The Sisters Network is a national 
organization of African American breast cancer survivors43, and currently has a 
membership of nearly three thousand women in thirty chapters across twenty-two 
states. The Sisters Network membership contributes to the International Registry 
by providing recruitment opportunities at their national as well as local meetings. 
Recruitment involves participants agreeing to provide access to medical records 
and saliva specimens suitable for DNA extraction and genotyping studies. In their 
2016 national conference held at Detroit Michigan, the UM comprehensive 
cancer center featured with educational talks, counseling opportunities and a 
chance to get involved in the lives of the very important group of breast cancer 
survivors. 
Long-term goals of this collaboration include studies of germline breast 
cancer risk in women with diverse racial-ethnic backgrounds in the United States 
compared to international populations.  
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We are in the process of establishing a cancer research institution in 
Ghana, that will serve as a model research institution for serve the western 
African sub-region. It is our hope that the institution, that is registered under the 
name, Research Institute of Health, Ghana (RIHG), will study chronic diseases in 
the African population with the hope of beret understanding the biology of these 
diseases and developing new interventions. It will partner with all the major 
Universities and teaching hospitals in Ghana, the west African sub-region and 
the United States.  
We enthusiastically look forward to this expanded research as a valuable 
contribution to precision medicine initiatives. We are also committed to ongoing 
investment in the breast oncology services available to patients in all of our 
partnering sites as well as throughout other low and middle income countries. 
Establishment of core biopsy programs, immunohistochemistry programs, and 
multidisciplinary tumor board conferences are examples of the services that are 
promoted through our research collaborative. 
Other investigators with an interest in this type of international cancer 
research should be mindful of evolving policies that regulate transport of human 
tissue via commercial airlines. Updates on regulatory requirements and 
restrictions can be obtained at the Centers for Disease Control website 
(http://www.cdc.gov/importation/index.html). Our group typically transported 
breast tissues for immunohistochemistry studies as formalin-fixed specimens 
embedded in paraffin blocks. The fresh specimens for PDX work were 
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transported in dry ice. Commercial carriers have regulations for labeling and 
packaging of dry ice, including maximum limits for quantity of dry ice that can be 
transported. Updates on these regulations can be accessed through the 
particular carrier’s “Dangerous Goods” office and website. Investigators should 
also work with their institution’s liaison to the Occupational Safety and Health 
Administration (OSHA) for training in handling dry ice, and further information can 
be obtained from OSHA directly (www.osha.gov).  
International partnerships represent a powerful and unique opportunity to 
advance insights regarding the etiology of domestic disparities in breast cancer 
burden related to racial-ethnic identity. These efforts also provide valuable 
cultural, academic and educational exchange programs as well as opportunities 
to strengthen the oncology services in under-resourced countries. Our program is 
certainly not unique; “medical missionary”- type work has existed for many 
decades. Hopefully this summary of our ten-year experience with international 
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Chapter 3 : Correlation Between African Ancestry, Triple Negative Breast Cancer 
and BRCA Gene Expression 
 
Abstract 
Triple negative breast cancer (TNBC) is the most common breast cancer 
subtype diagnosed in women with BRCA1 mutation. It is more common among 
African American (AA) and western sub-Saharan African breast cancer (BC) 
patients compared to White Americans (WA) and Europeans. Though women in 
western sub-Saharan Africa have the highest single institutional incidence of BC, 
there is very little known about the prevalence of BRCA mutation among these 
patients. Also, very little is known about TNBC in east Africa.  Here we compared 
the prevalence of TNBC between Western Sub-Saharan African, Eastern African, 
AA and WA women. Considering the shared phenotype between TNBC patients 
and patients with BRCA mutation, we evaluated the expression of the BRCA and 
BRCA2 protein in FFPE samples from Ghanaian BC patients and also began 
studies evaluating the occurrence of BRCA1and BRCA2 germline and somatic 
mutations in Ghana TNBC patients. 
 We first evaluated Invasive BC diagnosed 1998-2014 by 
immunohistochemistry: WA and AA patients from the Henry Ford Health System 
in Detroit, Michigan; Ghanaian/west Africans from the Komfo Anokye Teaching 
 58 
Hospital in Kumasi, Ghana; and Ethiopian/east Africans from the St. Paul’s 
Hospital Millennium Medical College in Addis Ababa, Ethiopia. Histopathology 
and immunohistochemistry for estrogen receptor (ER), progesterone receptor 
(PR) and HER2/neu expression was performed at the University of Michigan on 
formalin-fixed, paraffin-embedded samples from all cases. 
We then performed IHC staining of TNBC tumors from Ghanaian patients 
for the expression of the BRCA1 and BRCA2 protein. We also sequenced six 
TNBC tumors from Ghanaian patients with match normal DNA obtained from the 
saliva.  
234 Ghanaian (mean age 49 yrs.); 94 Ethiopian (mean age 43); 271 AA 
(mean age 60); and 321 WA (mean age 62; P=0.001 for the four comparisons) 
patients were compared. ER-negative and TNBC were more common among 
Ghanaian and AA compared to WA and Ethiopian cases (frequency ER-
negativity 67.5% and 37.1% versus 19.8% and 28.7% respectively, p<0.0001; 
frequency TNBC 53.2% and 29.8% versus 15.5% and 15%, respectively, 
p<0.0001). Among patients younger than 50, prevalence of TNBC remained 
highest among Ghanaians (50.8%) and AA (34.3%) compared to WA and 
Ethiopians (15.9% in each); (P<0.0001). more than 50% of Ghanaian TNBC 
patients had no expression of both BRCA1 and BRCA2 proteins and we 
identified novel BRCA1/2 gene mutations in Ghanaian tumors, some that can 
lead to truncation to of the protein. 
Conclusions:  
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This study confirms an association between TNBC and West African 
ancestry; TNBC frequency is highest in west African women, intermediate among 
AA patients consistent with genetic admixture following the west Africa-based 
trans-Atlantic slave trade and lowest in Eastern African and WA women. TNBC 
frequency was low among Ethiopians/East Africans; this may reflect less shared 
ancestry between AA and Ethiopians. The very high occurrence of absent 
expression of BRCA1 and BRCA2 protein in Ghanaian patients and the relatively 
high frequency of germline mutations indicate the need to study BRCA and its 
associated genes in this understudied population.
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Introduction 
African American women bear a disproportionately high share of the breast 
cancer mortality burden in the United States, and this outcome disparity has 
been increasing. Socioeconomic disadvantages that are more prevalent in the 
African American community, such as poverty rates and being under-insured, 
undeniably contribute to barriers in accessing the health care system and result 
in poorer cancer control overall.  
However, there are features characterizing the epidemiology of breast 
cancer in African Americans that cannot be easily ascribed to socioeconomic 
inequities. Until recently population-based lifetime incidence rates of breast 
cancer have been lower for African American compared to White American 
women; the average age at breast cancer diagnosis is younger for African 
American patients; and African American women have higher rates of hormone 
receptor negative and the biologically more-virulent triple negative tumors. Lastly, 
population-based incidence rates of male breast cancer are higher in the African 
American community. 
A similar pattern characterizes BC in patients with BRCA1 mutation: they 
occur at a younger age, are aggressive, have a higher incidence of TNBC and 
have a higher incidence of male breast cancer. I western Sub-Saharan Africa, 
available data indicates a similar pattern of BC phenotype with the incidence of 
TNBC being even higher; as high as 80%. There is very little reported however 
on the incidence of BRCA mutations in these patients. This is largely due to the 
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cost involved in BRCA testing, and that lack of availability of the test to those who 
may be able to afford. It is however very important to know the prevalence of 
BRCA mutations in this population. 
We therefore sought to evaluate the question of whether African ancestry 
is associated with some heritable marker of risk for particular patterns of breast 
cancer pathogenesis by studying breast tumor phenotypes in four different 
population subsets: White Americans; African Americans; Ghanaians 
(representing west Africa); and Ethiopians (representing east Africa). 
In the Ghanaian population, we first performed a preliminary analysis by 
staining for BRCA1 and BRCA2 protein using IHC staining of FFPE samples 
from the patients. We also investigated the incidence of BRCA1 and BRCA2 and 





This research effort represents clinic pathology studies that are 
components of an international breast cancer registry, approved by the 
Institutional Review Boards of the University of Michigan; the Henry Ford Health 
System; and the human research ethics approval and/or institutional 
departmental approval equivalents for the Komfo Anoyke Teaching Hospital in 
Kumasi Ghana (Committee on Human Research Publication and Ethics, Kwame 
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Nkrumah University of Science and Technology) and the St. Paul’s Hospital 
Millennium Medical College in Addis Ababa, Ethiopia. Samples and results were 
de-identified/anonymized prior to analyses. 
 
Pathology and Immunohistochemistry  
Histopathology to confirm the diagnosis of breast cancer and 
immunohistochemistry for molecular marker studies were performed on the 
specimens from African American and White American cases by the Department 
of Pathology at the Henry Ford Health System. Evaluation of the Ghanaian and 
Ethiopian tumor specimens were performed at the University of Michigan North 
Campus Research Complex. Nuclear expression of hormone receptor (ER and 
PR) proteins was detected with specific monoclonal antibodies using a labeled 
streptavidin-biotin immunoperoxidase method. The immunohistochemical assay 
was performed on deparaffinized formalin-fixed tissue sections of the 
specimens.  Monoclonal mouse antibodies to human ER (DAKO clone ID5) and 
to human PR (DAKO clone PgR636) were used with a DAKO automated 
immunostainer following the manufacturer’s protocol. Immunohistochemistry for 
HER2/neu staining was performed using the HerceptTest (DAKO, Glostrup, 
Denmark), an FDA-approved clinical test that qualitatively identifies by light 
microscopy p185 HER2 overexpression in breast cancer cells. Molecular marker 
staining was interpreted by in compliance with ASCO/CAP guidelines and as per 
Fitzgibbons et al1-3. Tumors were scored as ER/PR-negative if they had less than 
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1% nuclear staining.  Confirmed ER and PR positive tumors served as positive 
controls, and normal adjacent mammary gland ductules present in the sections of 
tumor served as internal positive controls for the hormone receptors. The 
expression of HER2 was scored based on recommendations from Fitzgibbons et 
al1. Grading was based on the degree and intensity of membrane labeling of 
tumor cells, on a scale from 0-3+, as follows: grade 0 (no observable labeling or 
faint, incomplete, or barely detectable membrane labeling in <10% of tumor 
cells), 1+ (faint, incomplete, or barely detectable membrane labeling in >10% of 
tumor cells), 2+ (incomplete and/or weak to moderate complete membrane 
staining in >10% of tumor cells, or complete, intense membrane labeling in <10% 
of tumor cells) or 3+ (intense, complete membrane labeling in >10% of tumor 
cells).  A specimen scored as 0 or 1+ was classified as HER2/neu negative, and 
specimens scored as 3+ were considered positive. Those specimens with a 
grade of 2+ were considered equivocal, and follow-up fluorescent in situ 
hybridization (FISH) was used to assess amplification of the HER2/neu gene in 
the cases with 2+.  
 
Exome Sequencing and Data Analysis 
Exome library construction:  150-200ng of patient normal and tumor were 
used for exome library construction.  The genomic DNA was sheared to sizes 
between 150-200bp using the Covaris S2 system as per manufacturer protocol.  
Libraries were constructed using an in-house protocol using a combination of 
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Kapa LTP kit and Agilent’ SureSelect Human All ExonV5 capture probes.  Exome 
libraries were quantified with Qubit high sensitivity DNA assay and size was 
determined with the BioAnalyzer using the High Sensitivity DNA Assay. Paired 
end NGS:  All NGS was carried out using Illumina HiSeq 2000 with a read length 
of 83 cycles x 7 cycles x 83 cycles.  Pooled libraries were first clustered onto 
flowcells using Illumina’s cBot and HiSeq Paired End Cluster Generation kits at a 
concentration of 14pM.  Analysis of the resulting data was done with an in-house 
developed pipeline. 
 
Ascertainment of Cases  
African American and White American: At Henry Ford Health System, 
women diagnosed with their first primary invasive breast cancer between 
January 1st, 2001 and December 31st, 2006 were identified from the Pathology 
Information System (Co-Path). The initial date of entry reflects the year that 
HFHS implemented an institutional wide policy mandating routine assessment of 
the HER2 biomarker for all cases of invasive breast cancer.  The other eligibility 
criteria were: 1) the initial diagnosis of breast cancer at HFHS; 2) AJCC TNM 
stages I-IV; and 3) insurance through the HMO plan. The first two eligibility 
requirements were imposed to minimize variation in the standards of the 
pathologic diagnostic criteria.  The last criterion was imposed to reduce the 
potential confounding effect of socioeconomic status, i.e. limited or no access to 
healthcare, on the pathologic prognostic indicators of breast cancer. Data on 
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date of birth/age at diagnosis, and racial-ethnic identity were collected from 
electronic medical records. 
Ghanaian: Samples were obtained through the archived resources of the 
Department of Pathology at the Komfo Anokye Teaching Hospital in Kumasi, 
Ghana. They reflected a convenience-based collection of invasive breast cancer 
specimens in women diagnosed 1998-2014. Patient age at diagnosis and gender 
was the only uniformly-available clinical feature on these cases, as provided by 
the Department of Pathology records. 
Ethiopian:  Samples were obtained through the archived resources of the 
Department of Pathology at the St. Paul’s Hospital Millennium Medical College in 
Addis Ababa, Ethiopia. They reflected a convenience-based collection of invasive 
breast cancer specimens in women diagnosed 2001-2014. Patient age at 
diagnosis and gender was the only uniformly-available clinical feature on these 
cases, as provided by the Department of Pathology records. 
 
Statistical Analysis 
Parametric and non-parametric statistical techniques, as appropriate, were 
performed to discern the distribution of clinic pathologic variables between 
African-Americans and White-Americans populations.   We then dichotomized 
women into two age groups, <50 years versus ≥50 years and conducted a sub-
set analysis to discern the distribution of clinic pathologic variables between 
African-American and White-American women younger than age 50 years. 
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To discern the potential association between African heritage and the risk 
of triple negative breast cancer, we developed multivariable cumulative logistic 
regression models.  We had data for three variables, age at diagnosis, breast 
cancer subtype and tumor grades.  We first estimated the individual effect of 
each variable and their interactions with the outcome of interest, breast cancer 
subtype.  Variables with a P-value of ≤0.10 were considered as the candidate 
variables.  Interactions between variables also were tested at P-value ≤0.05.  
The final model included three candidate variables, age at diagnosis, tumor 
grade and ethnic heritage.  All statistical tests were two-sided and analyses were 




Tables 1 and 2 demonstrate the clinic pathologic features for the 272 
African American compared to 321 White American patients from the Henry Ford 
Health System, revealing statistically significant higher frequencies of high-grade, 
estrogen receptor-negative and triple negative tumors among the African 
American cases; frequency of HER2/neu-overexpressing tumors was similar 
between these two groups. The African American patients had a numerically but 
statistically non-significant younger mean age at diagnosis compared to the 
White American patients (60 versus 62; p<0.09). The AA patients had a similar 
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stage distribution compared to the WA patients overall and in the subset analysis 
of patients younger than age 50 years.  
As shown in Table 3, both of the American population subsets had older 
mean ages at diagnosis compared to the 234 Ghanaian patients (mean age 49 
years) and the 94 Ethiopian patients (mean age 43 years; p<0.001). High-grade 
pathology was significantly more common among the tumors of the African 
American, Ghanaian, and Ethiopian patients compared to those of the White 
American patients (50.4%; 53.8%; and 53.6% compared to 33.7%, respectively; 
p<0.001). 
Figure 1 demonstrates results of the molecular marker and phenotype 
comparisons. Frequency of ER-negative and triple negative tumors was highest 
in the Ghanaians (67.5% and 53.2% respectively), lowest in the White Americans 
(19.8% and 15.5%, respectively), and intermediate in the African Americans 
(37.1% and 29.8%, respectively). Frequency of these phenotypes in the 
Ethiopian cases was similar to the White American cases (28.7% and 15.0%, 
respectively). Differences in the distribution of these phenotypes across all four 
population subsets were statistically significant  
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Table 3-1: Clinic pathologic features of African American and White American 




BC= breast cancer; Dx= diagnosis 
 (p=0.0001 for ER; p<0.0001 for TNBC). Frequency of HER2/neu-
overexpressing tumors was low in the White American, African American, and 
Ghanaian cases (16.7%, 18.7% and 20.1%, respectively) but significantly higher 
in the Ethiopian cases (33.3%; p=0.0048). As shown by Figure 1b, subset 
analysis for the patients younger than age 50 years revealed patterns similar to 
those seen for patients of all ages. Frequency of triple negative tumors was 
highest in the Ghanaian patients (50.8%), lowest in the White American and 
Ethiopian patients (15.9% in each), and intermediate in the African Americans 
(34.3%; p=<0.0001). Among patients younger than 50 years, the frequency of 







Table 3-2: Clinic pathologic features of African American and White American 













Table 3-3: Clinic pathologic features of African American, White American, 







Figure 3-1: A comparison of breast cancer phenotypes across different ethnicities: 
a Comparison of phenotypes between African American, White American, 
Ghanaian, and Ethiopian breast cancer patients. b Comparison of phenotypes 
between African American, White American, Ghanaian, and Ethiopian breast 
cancer patients younger than 50 years 
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Table 3-4: Comparisons of phenotypes between couplets of population subsets. 
 
Table 4 demonstrates phenotype distributions for the four different patient 
populations as couplet comparisons, revealing that the Ethiopians and White 
Americans were the most similar (p=0.77). Statistically significant differences 
were observed in comparisons of all other couplets, largely driven by the highest 
frequencies of triple negative tumors in the Ghanaian patients and moderately 














































































Expression of BRCA1 and BRCA2 protein in Ghanaian TNBC patients. 
With the confirmation that the Ghanaian patients had the highest 
proportion of TNBC, we sought to determine if this observation is related in any 
way to BRCA gene expression. We performed an initial screening on FFPE 
samples from 72 invasive Ghanaian TNBC for the expression of the BRCA1 and 
BRCA2 protein by immunohistochemistry. The purpose of this evaluation was to 
score positive or negative BRCA1 and 2 status in the slides provided (Figure 2). 
Since BRCA1 and 2 are nuclear proteins, and the current literature scores based 
on nuclear localization, samples were scored as positive for immunolabeling for 
either marker when nuclear localization was observed. Cytoplasmic staining was 
considered background, and not taken into consideration of positive status. 
BRCA1 staining was generally very specific, with little cytoplasmic staining or 
other background. However, BRCA2 staining was often cytoplasmic and 
granular, and thus background staining was observed in many sections. 
However, several specimens were completely negative for each marker, with no 
background staining. 
Fig.2 shows the expression of the BRCA1 and BRCA2 proteins. In 28 of 
the tumors (39%) there was no expression of either BRCA1 or BRCA2. 20 
tumors (28%) expressed both proteins. 13 tumors (18%) expressed the BRCA1 




Figure 3-2: BRCA immunostaining 
BRCA1 (left column) and BRCA2 (right column) immunolabeling in human breast cancer 
samples. Control tissues (top) show focal nuclear immunoreactivity to BRCA1 (left, 
arrowheads) and diffuse nuclear immunoreactivity to BRCA2 (right). Samples B/2050 and 
B/1649 show diffuse negative immunoreactivity to antibodies for BRCA1 (left) and BRCA2 
(right), respectively. Sample EO BH showed multifocal positive nuclear immunoreactivity for 




whiles 5 tumors (7%) expressed the BRCA2 and not BRCA1. 46% of the 




Several different genetic and epigenetic alterations including mutations, 
promoter methylation and post-translational alteration (silencing) may account for 
the loss of protein expression observed here.  To have some understanding of 
the cause of the protein loss, we performed whole exome sequencing on 6 
Ghanaian TNBC tumors and matched normal DNA extracted from the respective 
patient’s saliva as described above. We used extensive bioinformatics analysis to 
 
Figure 3-3: Results of BRCA1 and BRCA2 IHC staining in Ghanaian BC patients 
BRCA1/2-; tumor had no expression of both BRCA1 and BRCA2 proteins. 
BRCA1/2+; tumor expresses both BRCA1 and BRCA2 proteins. BRCA1+/BRCA2-
; tumors express the BRCA1 and not BRCA2 protein. BRCA1-/BRCA2+: only 
BRCA2 protein is expressed. ND; non-diagnostic. 
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identify somatic variants and germline mutations in these tumors. Bioinformatics 
was performed by the Jun Li lab, UMICH. 
 
 
There are 7 tumor/normal sample pairs from TNBC patients from Ghana, 
Africa. Normal DNA extracted from saliva specimens, and tumor DNA extracted 
from frozen tumor samples. 14 samples were exome sequenced using Illumina 
Hiseq2000 in 2 batches. First batch has sample.ID P1, P5, P6, and P9 and 
second batch has sample.ID P4410, P4430 and P4440. Each sample was 
 
Figure 3-4: Pipeline for somatic variant calling. 
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spread across 3 lanes. We used the following pipeline for DNA processing 
(Figure 1). The coverage varies between 27X to 69X and the average is ~50X. 
First batch have relatively lower coverage than the 2nd batch. After data 
processing, we used MuTect and VarScan2 to call the somatic variants. Table 5 
summarizes the number of indels and SNVs identified in each patient tumor. We 
observed as few as 4 Indels in P4110 tumor and 8 in patient P4130. 
 
 
 Somatic SNVs : predicted by MuTect and filter by Allele Frequency in normal samples 
less than 0.05. somatic Indels : predicted by VarScan2 (p-value<0.01). Filter: Allele 
Frequency in normal samples less than 0.1 and alternative allele has less than 3 
copies. 
 
Recurrently Mutated Genes 
After cross comparing the exonic variants in each sample, we have 
identified 35 recurrent mutated genes present in more than one sample, within 30 
recurrent genes, like NOTCH1, TNN and TNF655 occurred in 2 samples and 
GMPS, EP400, TP53, PPP2R2B, and PKHD1L1 occurred 3 or 4 samples. Table 
6 shows the list of genes that were recurrently mutated in the 6 samples.  






Germline mutation analysis was also performed on these samples with 
emphasis of the BRCA1 and BRCA2 and its pathway-associated genes on four 
of the patient sample pairs. (P1, P5, P6 and P9).  In sample P1, germline 
analysis of exome data revealed a novel BRCA2 nonsense variant that would 
likely truncate the vast majority of the protein.  Although this mutation has never 
been reported, it could be significant given the likely functional impact of the 
mutation. In sample P6, we identified 4 rare previously reported BRCA2 germline 
variants, however none were deemed pathogenic by ClinVar. In patient P9, there 
was one BRCA1 and two BRCA2 variants, however these were rare previously 
reported variants that were not deemed functionally or clinically relevant.  





A meta-analysis from ten years ago evaluated survival rates of more than 
thirteen thousand African American and seventy-five thousand White American 
breast cancer patients, and found that African American identity was associated 
with a statistically significant outcome disadvantage, even after adjusting for 
socioeconomic status (mortality hazard 1.28; 95% confidence interval 1.18-
1.38)4. The importance of tumor biology in the complex disparities picture was 
highlighted in the 2015 Annual Report to the Nation on the Status of Cancer5, 
demonstrating that population-based incidence rates of triple negative breast 
cancer are approximately two-fold higher for African Americans compared to all 
other population subsets, and this pattern is seen in all age categories. 
Population-based incidence rates of male breast cancer are also higher for 
African Americans compared to White Americans, and a study from the California 
Cancer Registry found a threefold higher frequency of triple negative tumors 
among African American men with breast cancer compared to White American 
men6. 
The American Cancer Society and the Surveillance Epidemiology and End 
Results Program have recently shown that breast cancer incidence rates have 
been increasing for African American women, to the point where they are now 
equal to the incidence rates in White American women7. Many of the advances 
made in systemic therapy for breast cancer have been in targeted therapies for 
endocrine-sensitive and HER2/neu-overexpressing tumors. Since the frequency 
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of triple negative tumors are higher in African American breast cancer patients, 
these treatment advances are less effective in this population subset. The 
disproportionate effectiveness of targeted therapies in African American breast 
cancer patients, coupled with the increasing incidence of breast cancer in African 
Americans has resulted a widening of the mortality disparity between African 
Americans and White Americans, which is now a 42% difference.  
Against this background landscape of worsening breast cancer survival 
disparities related to racial-ethnic identity, this study evaluated the association 
between African ancestry and triple negative breast cancer by studying four 
different patient populations: African Americans; White Americans; Ghanaians 
(representing west Africa) and Ethiopians (representing east Africa). The two 
populations of African patients were significantly younger than the American 
patients, but this pattern is likely heavily influenced by the shorter overall life 
expectancy of individuals born in low and middle-income countries. We also 
found highest frequencies of ER-negative and triple negative tumors in African 
American and west African/Ghanaian breast cancer patients. White Americans 
and Ethiopians had similarly low frequencies for these phenotypes. Interestingly, 
frequency of HER2/neu-overexpressing tumors was elevated among Ethiopian 
breast cancer patients compared to the three other population subsets. These 
patterns persisted in subset analyses looking at patients younger than age 50 
years. 
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Our study suggests that breast cancer patterns of African Americans are 
similar to those of west Africans, but differ from those of east Africans. Patterns 
of the Africa diaspora and forced population migration through the slave trade 
from several centuries ago may explain these observations8-10. The colonial-era 
trans-Atlantic slave trade, which was largely controlled by the Europeans, 
resulted in west Africans (including the ancestors of present-day Ghanaians) 
being brought to the Americas. In contrast, the slave trade from east Africa was 
controlled by Arab groups, and brought ancestors of contemporary Ethiopians to 
the mid-East and Asia. African Americans therefore are likely to have more 
shared ancestry with west Africans/Ghanaians compared to Ethiopians. 
Confirming that our study cases are broadly representative of national and 
international populations was challenging, owing to the paucity of published data 
on breast cancer phenotypes in Africa. Table 5 summarizes comparisons of our 
study African American and White American cases to population-based data 
from the SEER Program7, demonstrating that patterns of disease in the HFHS 
cases were indeed comparable to national statistics. The study Ghanaian cases 
were generally comparable to other reports of breast cancer in Ghana with 
regard to the young median age at diagnosis and the high frequency of ER-
negative as well as triple negative tumors11,12. A note-worthy exception was the 
study by Adjei et al13, comparing a relatively small number of Ghanaian breast 
tumors (n=51) to the tumors of Norway, with all immunohistochemistry performed 
at the Norwegian collaborating cancer facility. This study found a frequency of 
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triple negative tumors of only 22% among the Ghanaian cases, however of note 
this study also reported a notably low frequency of triple negative breast cancers 
in the comparison Norwegian population, at only 7%. The frequency of TNBC 
among Ghanaian cases therefore was threefold higher than the comparison 
Norwegian cases, a statistically significant difference (p=0.018). Very little data 
are available on molecular marker expression of breast cancers in Ethiopia, but 
work conducted by a German group has reported similarly low prevalence of ER-
negative breast cancer in Ethiopian cases from Addis Ababa University (34.7%) 
compared to our St. Paul’s Millennium Hospital study (28.7%)14. Interestingly, 
SEER-based data evaluating breast cancers among women in the United States 
diagnosed 1996-2008 with diverse African ancestral backgrounds confirms 
differences in frequency of ER-negative breast cancer related to heritage15. East 
African-born patients (186 patients, predominantly from Ethiopia or Eritrea) had 
ER-negative tumors in 22% of cases, compared to 33% ER-negative tumors 
among 143 west African-born patients (mostly from Nigeria). Frequency of ER-
negative tumors among White Americans (18%) was similarly low as that 
observed among east African-born patients. In contrast, US-born African 





Table 3-7: Comparison of study patient populations with other reported studies of 




ACS/SEER= American Cancer Society/Surveillance Epidemiology and End Results 
Program; Dx= diagnosis; ER= estrogen receptor; TNBC= triple negative breast 
cancer; yrs= years. 
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Approximately 7% of breast cancer cases in the general population are 
estimated to harbor mutations in the BRCA gene; these women are found 
primarily in families characterized by multiple cases of the early onset of breast 
cancer16. The incidence of BRCA mutation is however very high in TNBC 
patients (30.8% needs reference).  
BRCA mutation prevalence differs as well by ethnicity and race: AA 
(20.4%), Ashkenazi Jewish (50%), Asian (28.5%), Caucasian (33.3%), and 
Hispanic (20%).17 
In patients with BRCA1 mutation, up to 70% of the BC are triple negative. 
There is a very high overlap in the morphologic and phenotypic characteristics of 
sporadic TNBC and BRCA1 associated BC and BC occurring in women with 
African ancestry; younger age distribution, high grade lack of expression of the 
estrogen receptor. These strong resemblances have been said to possibly 
suggest a commonality in one or more defects in the functions of the BRCA1 
pathway for both BRCA1-associated and sporadic TNBC18. Identification of 
TNBC patients with BRCA1 mutation has helped in identifying family members 
who are at an increased risk for developing breast cancer and also for planning 
treatment options. In western Sub-Saharan Africa, where there is the reported 
highest incidence of TNBC, very little is known about the prevalence of BRCA 
mutations. Here we report an unusually high incidence of loss of expression of 
BRCA proteins; 57% of the tumors had loss of expression of both BRCA1 and 
BRCA2 with 39% having loss of expression of BRCA1, though the exact cause of 
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loss of protein expression is not fully understood, our sequencing data shows a 
high incidence of BRCA variants in the Ghanaian TBNC tumors with the 
identification of novel mutations that would likely lead to truncation of the protein. 
This preliminary data suggests the possibility that women in Western sub-
Saharan Africa may harbor a very high incidence of BC susceptibility genes.  
 
Clearly, more research is warranted in the study of breast cancer related to 
African ancestry. Our study suggests that west African ancestry is associated 
with inherited susceptibility for hormone receptor negative and triple negative 
breast cancer. It also suggests the possibility of a very high incidence of BRCA 
gene alterations in this population. Future work should strive to document 
population-based data on breast cancer incidence and mortality in different areas 
of Africa and also study the incidence of BRCA mutations in African TNBC 
patients. This research and its relevance to breast cancer disparities in the 
United States can be refined by utilizing germline genotyping studies and 
Ancestry Informative Markers to quantify extent of east versus west African 
ancestry in African American breast cancer patients19. Furthermore, gene 
expression studies of tumors in breast cancer patients with African ancestry are 
needed so that we can define the extent to which TNBC subtypes are similar or 
different across diverse populations20. 
This type of research holds great promise with regard to the critically 
important and relevant goals of understanding disparities in breast cancer burden 
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related to racial-ethnic identity domestically; investing in the oncology care 
systems of LMIC; and identifying additional markers of hereditary susceptibility 
for triple negative breast cancer.
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Chapter 4 : ALDH Expression Characterizes Tumor Initiating Stem Cells in Triple 
Negative Breast Cancers across Different Ethnicities. 
 
Abstract 
Triple negative breast cancer (TNBC), one of the most aggressive breast 
cancer subtypes, carries a guarded prognosis and is the only subtype for which 
there are no approved targeted therapies. Chemotherapy is the mainstay of 
treatment both in the neo- and adjuvant settings and for metastatic disease. 
Improving patient outcomes requires a better understanding of the genotype and 
phenotypes of cells that mediate aggressiveness and metastases. 
In the US, the incidence of TNBC is highest in women with African 
ancestry (AA); in western sub-Saharan Africa, single-institution studies show that 
TNBC constitutes 40- 80% of all breast cancers. Given the Caucasian/AA 
survival disparity in breast cancer, there is an urgent need to find actionable 
targets in TNBC of all ethnicities, but especially in TNBC in AA, which are 
suspected to be more aggressive. There is the urgent need to better understand 
the biology of TNBC in order to develop effective therapies targeting genes and 
pathways responsible for metastatic behaviors. 
 Breast cancer stem cells, the small population of cells in breast 
tumors that have been shown to mediate breast tumor initiation, metastasis and 
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resistance to conventional therapy have also been reported to mediate the 
heterogeneity of TNBC and are especially abundant in TNBC in women with 
African ancestry.  
In this study, we sought to find differentially expressed and activated genes 
and pathways in the stem cell populations of patient derived TNBC xenografts 
from Ghanaian, African American, and Caucasian patients. By these analyses 
we identified that the ALDH1 expressing cancer stem cells of these tumors 
segregate apart from bulk populations and CD24/44 stem cells, and were 
enriched with genes and pathways that are involved in tumor metastasis 
including the WNT, MAPK and TGF-beta pathways. We also identified novel 
genes that are significantly up-regulated in this population that may serve as 











Triple negative breast cancer (TNBC), defined by having less than one per 
cent expression of the estrogen and progesterone receptor,1 and no 
overexpression of the HER2 oncogene;2,3 carries a guarded prognosis. TNBC 
has a 5-year overall survival of 64% compared to 81% in non-TNBC; TNBC has 
the highest rate of visceral and distant relapse, and, importantly, the shortest 
survival after the onset of clinical metastasis4-6. It appears that the significant 
gains in survival from breast cancer achieved in the last 2 decades have largely 
bypassed TNBC patients. As there are no approved targeted therapies for TNBC, 
chemotherapy is the mainstay of treatment in either the neoadjuvant setting or 
after loco-regional therapy with surgery and radiotherapy 3,7 and for metastatic 
disease outside of clinical trials. Patients with TNBC have a higher rate of 
complete pathological response after neoadjuvant chemotherapy (22% v 11%; P 
= .034) as compared to non-TNBC5,8. However, for those 80% of TNBC patients 
with partial pathologic response, their survival is much worse than for patients 
with non TNBC with similar response. This apparent paradox is due to TNBC 
patients with residual disease having a much rapid relapse and much lower 
survival once metastases are detected4,6. The molecular complexity and extreme 
heterogeneity of TNBC makes it difficult to define and credential molecular 
targets. Several attempts have been made to classify TNBC into subtypes, with 
the aim of describing prognostic categories9-12; however, these sub-
classifications have not yet influenced clinical management. 
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An abundance of evidence supports the existence in breast cancer of 
tumor initiating cells with self-renewing potential, termed breast cancer stem cells 
(BCSC), which play a major role in tumor recurrence and metastasis13,14. These 
cells have been shown to be especially abundant in TNBC15,16,17, are key 
mediators of resistance to conventional chemotherapy and radiotherapy,18-20 and 
contribute to the heterogeneity of TNBC 21. The BCSC populations are 
themselves diverse and can be isolated from the tumor mass using fluorescent 
activated cell sorting (FACS) when they are CD44+/CD24-/EPCAM+22,23. 
Furthermore, using the ALDEFLUOR assay, stem-like cells can also be isolated 
by measuring the activity of the intracellular aldehyde dehydrogenase enzyme in 
intact breast cancer cells15. ALDH+ BCSC have been shown to mediate 
metastasis and poor clinical outcomes in breast cancer24. While the existence of 
phenotypic BCSC is supported by a large body of preclinical and clinical 
evidence, the pathways that contribute to the maintenance of this cell population 
have not yet been clearly defined in patient tumors.25 
Another striking characteristic of the epidemiology of TNBC is its high 
prevalence in women with African ancestry26 compared to Caucasian women. 
While African American women have a lower incidence of breast cancer than 
European American women in the USA, multiple studies have reported a much 
higher proportion of TNBC as a component of all breast cancers in sub-Saharan 
African women with pure African ancestry. The proportions of TNBC in all breast 
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cancers by race are 10-21%, 21-46% and up to 82% for Caucasians, African 
Americans (AA), and sub-Saharan Africans respectively26-31.  
The high incidence of TNBC in women with African ancestry has been 
suspected as one of the potential determinants for the higher mortality observed 
in African American women with breast cancer, which has been maintained over 
the last 3 decades. Importantly, previous reports specifically have associated 
expression of ALDH1, the main protein associated with the ALDEFLUOR assay 
activity, with TNBC and aggressive breast cancers in African women17. Indeed, in 
our previous work, we showed a significantly high expression of ALDH1 in breast 
lesions (both benign and malignant) of Ghanaian women. We also showed a 
higher expression of ALDH1 in TNBC as compared to other breast cancer 
subtypes16in this native African population. It is important to note that AA in the 
United States represent varying degrees of genetic admixture from local as well 
as several ancestral populations, including “true African” ancestry originating 
largely from western Sub-Saharan African through forced migration from the 
trans-Atlantic slave trade. Thus, it is possible that African ancestry might be 
associated with a heritable risk for developing TNBC and studies of pathway 
alterations in ancestrally pure populations compared to admixed populations may 
offer a new understanding of the biology of this disease. 
We have therefore hypothesized that the key to unraveling the complexity 
of TNBC and thus finding new targets for its treatment lies in understanding 
signaling integration and gene expression in the BCSCs of TNBC in women with 
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African ancestry in comparison with other ethnicities, looking both for common 
changes and unusual new genes or pathways that may be altered to render this 
subtype quite different from the other breast cancer subtypes. 
So far, most of the data on the biology of TNBC was generated using cell 
lines developed mainly from Caucasian patient tumors, which, by virtue of their 
prolonged passage in 2D cultures, may not serve as a true representation of the 
heterogeneous nature of TNBC.  This study utilizes sorted BCSC populations 
from unique patient materials to address the gap in knowledge about genetic and 
pathway determinants of the phenotype that is TNBC. In this article, we will also 
discuss our unique approach to finding novel targets in the BCSC of TNBC using 





Patient Derived Xenograft Generation 
The PDXs that were used for this study were generated at three locations: 
The University of Michigan (UM), Van Andel Institute (Grand Rapids, MI) and 
Baylor College of Medicine (Houston, TX). For the PDXs generated at UM, the 
samples were obtained from patients receiving treatment either at the Komfo 
Anokye Teaching Hospital (KATH) in Kumasi Ghana or at the UM Hospital. 
Institutional Review Board approval was obtained at both institutions and patient 
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informed consent was also obtained. At KATH, excess patient tumor tissue was 
taken from the operating room, cut into small pieces and slow frozen at -80oC in 
10% DMSO/ 90%FBS. The samples were then transported overnight on dry ice 
in a commercial flight to UM. For samples obtained from patients, undergoing 
breast cancer treatment at the UM, excess patient biopsy sample was obtained.  
For tumor implantation, the tumor pieces were rapidly thawed and rinsed off with 
HBSS or PBS, cut into smaller fragments (approximately 2 mm in diameter), 
mixed with matrigel (BD), and injected into the mammary fat pad of female 
NOD/scid/IL2Rgnull (NSG) mice with an 18-gauge needle, 25 µl of matrigel per 
injection site. Xenograft tumors were taken out when they reached a size of 1 to 
1.5 cm. PDXs generated at Van Andel Institute and Baylor College of Medicine 
were re-implanted in NSG mice. 
 
Tissue Dissociation and Flow Cytometry 
Xenograft tumors were digested using the Tumor Dissociation Kit (Miltenyi 
# 130-095-929) and the gentleMACS Octo Dissociator with the Human Tissue 
dissociation protocol, running the “gentleMACS Octo Dissociator program 
37C_h_TDK_1 (Miltenyi). Mouse cells were removed using the Mouse Cell 
Depletion Kit (Miltenyi # 130-104-694) and MultiMACS Cell24 Separator Plus 
(Miltenyi). The cells were then stained with: LIVE/DEAD Near-IR Fixable Dead 
Cell Stain (Invitrogen, Catalog #L10119) anti-mouse MHC Class I (H-2Kd) eFluor 
450 (eBiosciences, Catalog #48-5957-80), Aldefluor (Stem Cell Technology, 
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Catalog #01700), CD44-APC (Clone G44-26; BD), CD24-PECy7 (Clone ML5; 
Biolegend), and EpCAM-PE (Clone EBA-1; BD). Half of the stained cells were 
incubated with DEAB (Stem Cell Technology, Catalog #01700), an inhibitor of 
ALDH. An aliquot of cells was also stained with Live-Dead Near-IR, anti-mouse 
H2KD eFluor 450, and mouse IgG1 isotype antibodies individually conjugated to 
APC, PECy7, or PE (BD). These isotype-stained cells were used to set gates for 
CD44 APC CD24-PECy7 and EPCAM PE. Single color controls were used for 
compensation. The DEAB control was used to set the gate for Aldeflour+ cells. 
Cell sorting was done on a MoFlo Astrios flow cytometer. 
 
Breast Cancer Stem Cells Whole Transcriptome Library Construction and 
Paired End NGS: 
BCSC populations from PDX samples from 5 women each of various 
ethnicities (African American, Caucasian, Ghanaian) were FACS sorted to sub-
select and collect ALDH+, CD24-CD44+EPCAM+ cells, and bulk cells. Total RNA 
was extracted from all 3 cell fractions using Single Cell RNA Purification kit 
(Norgen Biotek Corp., Ontario, Canada) following the manufacturer’s protocol.  
Quality and quantity of total RNA was assessed using Agilent 2200 TapeStation 
Instrument (Agilent Technologies, Santa Clara, CA) and NanoDrop 1000 
Spectrophotometer (Thermo Fisher Scientific, Waltham, MA), respectively. 
Whole Transcriptome libraries with an initial input of 10ng RNA were constructed 
using Nugen Ovation RNASeq V2 (NuGen, San Carlos, CA) for cDNA generation 
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and Kapa LTP Library preparation kit (Kapa Biosystems, Wilmington, MA). The 
libraries were then sequenced on the Illumina HiSeq platform (Ilumina, San 
Diego, CA) with 83 cycles x 7 cycles x 83 cycles read length.  
 
Data Analysis 
Raw sequencing data in the form of .bcl files were converted to .fastq files 
using bcl2fastq 1.8.4 (Ilumina, San Diego, CA) and aligned against the human 
reference genome GRCh 37.74 using STAR 2.3.1 Aligner with default 
parameters. (https://github.com/alexdobin/STAR). Aligned reads were assigned 
to genomic features (GRCh37 genes) and quantified by HTSeq-count 0.6.1. 
(http://www-huber.embl.de/users/anders/HTSeq/doc/overview.html). HtSeq-count 
generated the CPM values (counts per million) for each gene of each samples. 
EdgeR was used to identify differential gene expression with both fisher-exact 
test and generalized linear models (FDR<=0.05), with an input of CPM value with 
log2 transformation. Prior to the PCA analysis, six samples (CA:3, AA: 3) were 
removed due to a poor data quality.  Log2 values of each patient’s bulk CPM 
were used for TNBC subtyping (http://cbc.mc.vanderbilt.edu/tnbc/). Pathway 
analysis was performed with iPathwayGuideTM (Advaita Bioinformatics, 
Plymouth, MI) and LRpath (lrpath.ncibi.org).  
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Tumorsphere Formation Assay 
Cells obtained from FACS sorting of PDX samples were plated in a 96-
ultralow attachment flat bottom plates (Corning) at 5,000 cells/well in 100ul of 
serum free media Serum-free media (SFM) contains: DMEM, 1X B27 (Gibco), 50 
ug/mL insulin, 1X non-essential amino acids, 10ng/mL EGF, 10 ng/mL bFGF, 
and antibiotics. Tumorspheres formed after 3-5 days and each experiment was 




Creating PDX based TNBC Models from Tumors of Women of Different 
Ancestries. 
We succeeded in implanting cancerous tissues directly from patients into 
immune deficient mice, thus providing a renewable source of tissue for 
experiments. Patient derived xenograft (PDX) tumors have been shown to 
conserve the gene expression, histology, and architecture of the original primary 
tumor from which they are developed32-34. To study the gene expression in 
BCSC, which typically constitute less than 1% of the total tumor mass, we 
needed a large renewable source of breast tumors. We first explored the 
possibility of creating PDX from TNBC patients in sub-Saharan Africa (Ghana). 




Figure 4-1: A. processing and stem cell characterization from the patient derived 
xenograft 
A.  Tumor biopsy collected directly from patients were used for the experiments; 
biopsy samples were divided for different experimental procedures. For each biopsy 
sample, a part was slow frozen and later implanted into NSG mice as described in the 
methods section.  Tumors were harvested once they reached to 1-1.5cm in diameter. 
Freshly harvested PDX tumors cut into small pieces were enzymatically digested and 
processed into single cells. Tumor cells isolated after the removal of mouse cells were 
stained and flow sorted. Three cell populations; BULK (Live, Human) ALDH+(Live, 
Human, ALDH+) and CD44+/CD24-(Live, Human, CD44+/CD24-/EPCAM+) were 
sorted for. Each sort was done for three biological replicates of the tumor all at the 
same passage. A total of 15 tumors including 5 African American, 5 Ghanaian and 5 
Caucasian were processed and analyzed as described above 
 
B: Clinical and pathological data of the patient and the primary tumor from which the 
PDX were developed respectively.  
GUM refers to tumors that were obtained from Ghana, MUM is for tumors obtained 
from UM patients, VARI for PDXs from Van Andel Institute and the one with numbers 
only are from Baylor College of Medicine 
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Anokye Teaching Hospital in Ghana, Africa. After obtaining institutional 
review board approval and patient informed consent, we operated on BC patients 
and obtained samples of their tumors. Figure 4-1A. These tumors were frozen 
and transported to the UM as described. A piece of the tumor was at the same 
time fixed in formalin to create FFPE from which slides could be cut and stained 
for H&E as well as immunohistochemistry studies to confirm the marker 
composition of the tumor, as shown in Figure 4-1A. A piece was also snap frozen 
for RNA and DNA extraction at a later time. Saliva was also collected to have a 
matched normal genomic DNA for tumor/normal genomic comparisons. In the 
process of acquiring these tumors from Ghana, we provided infrastructural, 
educational, and technical support to the faculty, staff, and patients of the 
hospital35. 
At the UM, frozen primary tumor samples were orthotopically implanted in 
mice to create PDXs as described. We made 8 trips to Ghana over a period of 
three years and obtained tumor from 36 breast cancer patients, 16 of whom had 
TNBC. We implanted ten of the TNBC tumors in immunosuppressed mice and 
developed PDXs from five of them. We also established two PDXs from TNBC 
tumors obtained from patients undergoing surgery at the UM after obtaining 
informed consent. In addition, we collected early passage established PDXs from 
our collaborators in Van Andel and Baylor hospital. Figure 4-1B shows the 
patient ancestry, age, and histology of the primary tumors from which the PDXs 
were developed. 
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For this study, we used five Ghanaian, five African American, and five 
Caucasian PDXs. All primary patient samples were TNBC (TNBC status was 
confirmed at  
the UM, Van Andel or Baylor). All patients had high-grade invasive ductal 
carcinoma (IDC). Thirteen of the patient samples were from primary tumors and 
 
 
Figure 4-2: schematic for flow sorting for bulk and stem cell sub-populations 
Single cells obtained from PDX was stained as described in the methods section. 
Sorting was first done to isolate live, Fig2 A and single cells, Fig B. Human cells were 
then gated of mice cells using Mouse H2KD in V450 channel, Fig C. Using cells 
stained with isotype controls, gates were set for APC (CD44) positive and PECy7 
(CD24) negative at 0.1. Fig D and PE (EPCAM) at 0.1, Fig F. Using cells incubated in 
DEAB, the gate was set for ALDH+ cells at 0.10, Fig I. Of the total stained cells, Fig 
E shows the percentage that is CD44+/CD24-, 0.17. In the CD44+/ CD24- 
population, 0.39% were EPCAM positive, Fig G. In the total population of EPCAM+ 
cells, 1.64 percent are CD44+/CD24-, Fig H. In the total population of stained cells, 




two from metastatic locations in the axillary lymph nodes (LN) and chest wall 
metastasis.  
 
Isolating Breast Cancer Stem Cells and Bulk Cell Sub-populations from 
Established PDX 
The expression of the cell surface markers CD44+/CD24-(low) as well as 
the intra cellular enzyme ALDH have both been used as markers to identify 
BCSC and also demonstrate the classic BCSC phenotype of self-renewal and 
mammosphere formation.15,23,36. It was however noted that some tumors may not 
express either or both of these markers22. Using florescent activated cell sorting 
(FACS), we describe here a systematic procedure for simultaneously isolating 
the ALDH+, CD44+/CD24-/EPCAM+ and the bulk cells (which is the general 
fraction of live human tumor cells, not depleted of stem cells), in the established 
PDXs. The tumor was first processed into single cells and stained as described 
above. Single color controls for EPCAM PE, CD44 APC, CD24 PECy7, V45 
H2KD, and A750 LIVE/DEAD were first used to set compensations for the FACS 
separation (Fig. 2). For each sample, two tubes of cell were stained as controls 
and one tube was stained for sorting. All cells were stained with the LIVE/DEAD 
reagent, figure 4.2A, and V450/ANTI MOUSE H2KD which is used to separate 
the human from mouse cells, figure 4.2C. During FACS sorting, a gate is set for 
fore scatter (FSC) vs. side Scatter (SSC) figure 4.2C. This is an arbitrary gate 
used to separate single viable cells from doublets and debris. The first tube of 
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control cells is stained with isotype controls for APC, PE, and PECy7 which are 
used to set the gates for CD44 (in APC channel), CD24 (in PECy7 channel) and 
EPCAM (in PE channel) each to 0.1 figure 4.2D and F, respectively.  
In figure 4.2D, the upper left quadrant represents the CD44+/CD24- 
population. The second control cells, containing cells stained with ALDH, 
CD44APC, CD24 PECy7 in the presence of DEAD which blocks the action of the 
enzyme Aldehyde Dehydrogenase is used to set the gate for ALDH+ cells at 
0.1%, figure 4.2I. With all gates set, cell sorting is done from the third tube with 
cells stained with LIVE/DEAD, ANTI-MOUSE H2KD, ALDH, CD44, CD24 and 
EPCAM. To obtain a CD44+/CD24-/EPCAM+ cell population, live, single, human 
cells were sorted in the APC vs PECy7 gate, E, (0.17% in this sample (GUM-13). 
The EPCAM+ cells are then sorted off the CD44+/CD24- fraction. As figure 4.2G 
denotes, in GUM13, 8.39% of all CD44+/CD24- cells were EPCAM+. The ALDH+ 
population was sorted of live, single human cells in the gate, pre-set with DEAB 
control, (13.20% in GUM13), figure 4.2J. A portion of the stained cells was sorted 
for the BULK population (these are LIVE, SINGLE and HUMAN). In all 15 PDXs, 




Table 4-1 shows the proportion of tumor cells represented by the different stem 
cell sub populations, in the 15 samples. Importantly, it was observed that in most 
of these tumors, only a small percentage of the CD44+/CD24- cells expressed 
EPCAM.  These may represent the claudin-low tumor subtype which has a low 
expression of luminal markers and a high expression of mesenchymal markers37.  
 




ALDH+ Stem Cell Population has a Distinct Gene Expression Profile from 
CD44+/CD24- and BULK Population, in TNBC PDXs from all Ethnicities.  
In order to better understand the biology of BCSCs in these ethnically 
diverse tumors, we performed RNA-seq on the isolated stem cell populations and 
compared the results to those obtained for the bulk cells. Total RNA was 
extracted from the isolated cells, (Table 4-2 shows the number of stem cells that 
was collected for each sample and the corresponding RNA integrity). Figure 4.3A 
summarizes the process we used for RNA sequencing and comprehensive 
bioinformatics analyses. We performed principal component analysis for 39 
samples, excluding only six samples with poor data quality. Interestingly, the 
results for the subpopulations of each tumor clustered based on the tumor of 
origin, that is, the three samples from each tumor clustered together, as seen in 








To better observe the effect of ethnicity or cell population, we performed 
mean centering of the triplet of samples from each tumor. Briefly, the average 
spectrum for each triplet was subtracted from the spectrum for each sample in 
the triplet. After mean centering,  
 
 





the ALDH+ samples separated out from the bulk and the CD44+/CD24-, 
regardless of the ethnicity. Surprisingly, there was no separation between the 
CD44+/CD24- and the bulk samples, figure 4-3C. To answer the question of 
whether the ALDH+ and the CD44+/CD24- cells are distinct sub-populations in 
these tumors, we performed PCA analysis of the ALDH+ and the CD44+/CD24- 
samples alone. Once again, ALDH+ samples separated out distinctly from the 
CD44+/CD24- samples figure 4-3D.  
 
Figure 4-3: PCA plots of the global gene expression of 45 samples from 15 PDXs. 
Fig3A shows the pipeline for sample processing, sequencing and data analysis for 
the sorted samples. Prior to the PCA analysis, six samples (CA:3, AA: 3) were 
removed due to a poor data quality.  Fig. 4B shows PC1 vs PC2 plot of gene 
expression for 39 sorted samples from 15 PDXs developed from women from three 
different ancestries. Fig. 4C shows the PC1 vs PC2 plot of the samples after mean-
centering the three samples from each tumor. Fig 4D, PCA plot showing PCA1 vs 




ALDH+ not CD44+/C24- Cells Exhibit Stem Cell Characteristics in Primary 
TNBCs.  
Previous reports have indicated that ALDH expressing stem cell are 
important for the stem cell phenotype observed in TNBC especially in women 
with African ancestry17. Thus, with the ALDH+ population separating out, we 
compared their ability to form tumor spheres with that of the other two cell 
populations: bulk and CD44+/CD24-. The sphere formation assay, as described 
in the methods section, was performed with sorted stem and bulk cell sub-
populations from three of the PDXs: VARI-068, VARI-004, and GUM-17, as seen 
in Fig 4. We observed that the ALDH+ cells formed a significantly higher number 
of spheres followed by the bulk cells, with the CD44+/CD24- cells forming the 
least number of spheres (figure 4-4) In the secondary passage, the ALDH+ cells 
maintained a significantly higher sphere formation over the bulk cells, with the 
CD44+/CD24- forming no spheres at the higher passage. 
 
In Primary TNBC ALDH+ Stem Cells are Characterized by a Distinct Gene 
Expression Profile.  
With the observation that the ALDH+ populations separate out from the bulk and 
CD44+/CD24- (which clustered together), and with the ALDH+ population 
forming significantly more spheres in 3D culture, we explored the genes and 





Figure 4-4: Tumorsphere formation assay for ALDH+, CD44+/CD24- and BULK cells 
from three different PDXs. 
A shows tumor spheres formed from the BULK, CD44+/CD24- and ALDH+ sorted 
cells from VARI-068 and VARI-004 respectively, both TNBC PDXs. Cells were plated 
as described in the methods. Graph showing the average number of spheres formed 
per well of the 96-flat bottom ultra-low attachment plate for VARI-068 C, VARI-004, D. 
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separate the ALDH+ sub-population from the other two sub-populations. We 
identified 272 genes that were differentially expressed between the ALDH+ and 
the CD44+/CD24- sub-populations, (p-value 0.0008, FDR 0.05).  
 
Of these, 168 genes were down regulated while 104 were up regulated in the 
ALDH+ sub-population. Using LRpath, we identified ten pathways that are 
enriched in the ALDH+, (Table 4-3) and five pathways that are down regulated 
with respect to the CD44+/CD24- sub-population (Table 4-4).  
 




The WNT and MAPK pathways were the most enriched in the ALDH+ 
population. TGF-beta signaling pathway was also significantly enriched in the 
ALDH+ cells. The pathways that were down regulated were mostly biosynthetic 
pathways, such as Aminoacyl-tRNA biosynthesis, N-Glycan biosynthesis and 
one carbon by folate. 
 
. Comparing the ALDH+ to the BULK populations, we identified 373 genes 
that were significantly differentially expressed (p-value <0.001, FDR < 0.05). Of 
these, 372 were up regulated with the gene XIST being the only gene that was 
significantly down regulated in the ALDH+ vs BULK comparison. Among the 
pathways that were significantly enriched in the ALDH+ vs BULK comparison 
were WNT, MAPK and TGF-beta. We identified 14 genes that were 
simultaneously differentially expressed between the ALDH+ vs the CD44+/CD24- 
as well as ALDH+ vs bulk (p-value <0.001, FDR < 0.05).  Thus, we have  
identified a set of 14 genes that separate the ALDH+ from CD44+/CD24- as well 
as BULK sub-populations, as seen in figure 4-5C. The three most significantly 
changed genes were CPXM1, MMP2, and PCDH7. CPXM1 is a gene that likely 
encodes a member of the carboxypeptidase family of proteins [provided by 
RefSeq, May 2010]. MMP2, (Matrix metalloproteinase 2) belongs to a broad 
family of zinc-dependent proteases that are important in extracellular matrix 
degradation, and MMP2 is important in breast tumor invasion and metastases 
and has been shown to mediate breast cancer brain metastasis38. 
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PROTOCADHERIN 7; PCDH7 or BRAIN-HEART PROTOCADHERIN; BHPCDH 
promotes the assembly of carcinoma-astrocyte gap junctions that promotes brain 
metastasis in breast and lung carcinomas. PCDH7 also activate pathways in 
brain metastatic cells (through activation of STAT1 and NFKB), by which they 
support tumor growth and chemoresistance39. PCDH7 has also been shown to 
induce bone metastases in breast cancer40. Thus two of the three most 
significantly altered genes with known functions, are involved in tumor 
metastases. 
 
Significant signaling interactions exist between the genes that are 
differentially altered in ALDH+ stem cells in primary TNBC.  
To better understand the signaling interactions between the genes that are 
differentially expressed between the ALDH+ and other cell populations, we first 
created a heat map with the genes that had the highest fold change difference  






between the ALDH+ and the CD44+/CD24- (FC >2). We also added the genes 
that belonged to the pathways that were most significant between these two sub-
populations using the IPATHWAY guide software, figure 4-5A. We identified two 
 
Figure 4-5: Heat map of significant genes and their known gene interactions 
Heatmap showing the normalized log2CPM values 96 genes. The heat map was generated 
with dataset from 96 gene with the most significant differential expression between the 
ALDH+, the CD44+/CD24- and the bulk populations. It was generated using the 
"pheatmap" function on the statistical software package R. Data was not clustered 
according to cell lines, but rather prearranged according to cell line conditions. Using gene 
ontology, we generated a map showing the signal relationship between all the genes that 
were up regulated in the ALDH+ samples. C. All the genes that were significantly 
differentially expressed between the ALDH+ and the CD44+/CD24-  
C 
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separate clusters of genes that are upregulated in the ALDH+ stem cells, 
separated by a cluster of genes that were downregulated in the ALDH+ 
population. Using gene ontology and David statistical software41 we identified 
known signaling interactions involving the genes that were upregulated in the 




Using PDXs, we are the first to create a renewable tumor resource from 
women with native African ancestry (Ghanaian) and establish a comparative 
gene profiling system between the BCSC of ethnically diverse tumors.  In this 
manner, we definitively demonstrate the existence of two distinct BCSC sub-
populations in primary TNBC. The ALDH expressing stem cells exhibited a gene 
expression profile that was significantly different from the bulk and the 
CD44+/CD24- stem cell population with the up-regulation of genes involved in 
metastasis in the ALDH-expressing stem cells. The importance of using new 
approaches to understand the biology TNBCs has become increasingly 
paramount as it becomes more evident that we are encountering a lack of 
success in translating initially potentially promising drugs for TNBC into the clinic.  
There is a dire need for credentialed new targets for rational signaling driven 
therapeutics. 
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Utilizing a series of novel sorting schemas, the relevant BCSC populations 
could be isolated to discern their gene expression profiles in comparison to each 
other and to the bulk cells. As BCSC have been robustly implicated in certain 
aspects of tumor aggressiveness such as metastatic growth and resistance to 
conventional therapy we hypothesized that there would be unique signatures of 
these stem-like cell subpopulations that may enable targeting them specifically, 
as part of multimodality approaches to attack TNBC and effect the highest 
potential benefit for patients13,14,18-20,42.  In particular, we and others have shown 
that the prevalence of TNBC is higher in women of African extraction than in 
Caucasian women and thus we also surmised that the differences in stem cell 
populations may lead to therapies that will in turn help ameliorate the mortality 
disparities between Caucasians and African Americans. 
Work by our group and others has demonstrated the existence of two 
distinct populations of breast cancer stem cells in breast tumors15,22. These are 
the CD44+/CD24- stem cells that are said to be mesenchymal-like (epithelial-to-
mesenchymal transition, EMT) and the ALDH+ stem cells showed to be 
epithelial-like (mesenchymal-epithelial-transition, MET)43 in primary breast 
tumors across all tumor subtypes. In this study focused on TNBC only, we have 
clearly demonstrated the existence on these two distinct populations of stem 
cells in TNBC. Interestingly however, in this study, we demonstrate that the 
ALDH+ stem cells are the only stem cell population that has a gene expression 
profile that is distinct and separate from the bulk population, as the CD44+/CD24- 
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did not separate out from the bulk cells. The ALDH+ stem cells displayed a gene 
profile pattern that would be considered mesenchymal-like with the up regulation 
of MMP2 and down regulation of KI67 (data not shown). Relative to the 
CD44+/CD24- stem cells, ALDH+ stem cells also had an up-regulation of 
pathways WNT, TGF-B, and MAPK, all of which are important for tumor 
metastasis and general therapeutic resistance. This is not surprising because the 
expression of ALDH1 has been shown to be important in TNBC as a whole and 
in TNBC in women with African ancestry in particular15,17.  
Although the tumors in our study did not exhibit a gene expression 
signature that segregated by ethnicity, a firm conclusion cannot be made on this 
point at this time due to the limited sample size and the high degree of 
heterogeneity exhibited by these TNBCs. We note that this study represents the 
only study of the biology of TNBC and stem cells in which two thirds of the 
sample population is women with African ancestry with half of them being from 
women with pure African ancestry.  
Recent studies suggest that ALDH1 expressing stem cells might be the 
cells of origin of basal breast cancers (TNBC), the subtype of breast cancer that 
occurs most commonly in patients with BRCA1 mutation and that the loss of the 
BRCA1 expression leads to the expansion of ALDH expressing cells44-46. In our 
previous work, we reported that benign breast tumors in Ghanaian women, (a 
population with the highest reported institutional based incidence of TNBC), have 
a very high expression of ALDH1, even higher than seen in the malignant 
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tumors16. The findings in this recent study that in aggressive TNBCs from women 
with African ancestry and Caucasian women, it is the ALDH expressing cells that 
represent the stem cell population is therefore very relevant to our findings. It will 
be important therefore to investigate the BRCA1 mutation frequency in African 
women with TNBC as well as downregulation of BRCA1 expression by other 
non-genetic means, both of which are speculated to be very high. Indeed, in our 
previous study (chapter 3), we identified that two-thirds of Ghanaian tumors did 
not express the BRCA protein.  
The existence of molecular differences between or within breast tumors 
(tumor heterogeneity) has been well documented in breast cancers in general 
and more specifically in TNBC. These molecular differences occur either 
between different patients with the same tumor type (intertumor heterogeneity) or 
within the same patient (intratumor heterogeneity), which can occur in different 
parts of the same tumor or between a primary tumor and its metastasis47-51. 
Heterogeneity contributes to development of therapy resistance and raises 
concern for researchers, clinicians and patients as to the ultimate effectiveness 
of targeted drugs or drug combinations. The 15 tumors that were used for this 
study exhibited profound intertumor heterogeneity with the samples from each 
tumor clustering tightly together. Despite this large degree of molecular 
differences between the tumors, there were a number of genes and pathways 
that were very significantly differentially expressed in the ALDH expressing stem 
cells compared to the other populations. Therefore, focusing on targeting the 
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genes and pathways we discovered in this study has the potential to lead to 
therapies that may be effective across ethnicities by eliminating the cells with the 
highest potential for mesenchymal motion and metastatic growth.  Taken 
together, we propose that our data supports the targeting of the ALDH1+ stem 
cell subpopulation, which may be an important adjunct strategy to conventional 
chemo radiation in TNBC.  
 
Acknowledgements: Work supported in part by grants Komen 
promise grant, the Breast Cancer Research Foundation (MW, SDM), the 




1. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical 
Oncology/College of American Pathologists guideline recommendations for 
immunohistochemical testing of estrogen and progesterone receptors in 
breast cancer (unabridged version). Arch Pathol Lab Med. Jul 
2010;134(7):e48-72. 
 
2. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human 
epidermal growth factor receptor 2 testing in breast cancer: American 
Society of Clinical Oncology/College of American Pathologists clinical 
practice guideline update. J Clin Oncol. Nov 1 2013;31(31):3997-4013. 
 
3. Malorni L, Shetty PB, De Angelis C, et al. Clinical and biologic features of 
triple-negative breast cancers in a large cohort of patients with long-term 
follow-up. Breast cancer research and treatment. Dec 2012;136(3):795-
804. 
 
4. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: 
clinical features and patterns of recurrence. Clin Cancer Res. Aug 1 
2007;13(15 Pt 1):4429-4434. 
 
5. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy 
and long-term survival in patients with triple-negative breast cancer. J Clin 
Oncol. Mar 10 2008;26(8):1275-1281. 
 
6. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern 
of metastatic spread in triple-negative breast cancer. Breast cancer 
research and treatment. May 2009;115(2):423-428. 
 
7. National Comprehensive Cancer Network. National Comprehensive 
Cancer Network Breast Cancer. 2015. 
 
8. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary 
tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. Apr 
15 2007;13(8):2329-2334. 
 
9. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast 
tumours. Nature. Aug 17 2000;406(6797):747-752. 
 
10. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-
negative breast cancer subtypes and preclinical models for selection of 
targeted therapies. J Clin Invest. Jul 2011;121(7):2750-2767. 
 122 
 
11. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. 
Mol Oncol. Feb 2011;5(1):5-23. 
 
12. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution 
spectrum of primary triple-negative breast cancers. Nature. Jun 21 
2012;486(7403):395-399. 
 
13. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Breast cancer cell lines 
contain functional cancer stem cells with metastatic capacity and a distinct 
molecular signature. Cancer research. Feb 15 2009;69(4):1302-1313. 
 
14. Dontu G, Abdallah WM, Foley JM, et al. In vitro propagation and 
transcriptional profiling of human mammary stem/progenitor cells. Genes 
Dev. May 15 2003;17(10):1253-1270. 
 
15. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of 
normal and malignant human mammary stem cells and a predictor of poor 
clinical outcome. Cell Stem Cell. Nov 2007;1(5):555-567. 
 
16. Schwartz T, Stark A, Pang J, et al. Expression of aldehyde dehydrogenase 
1 as a marker of mammary stem cells in benign and malignant breast 
lesions of Ghanaian women. Cancer. Feb 1 2013;119(3):488-494. 
17. Nalwoga H, Arnes JB, Wabinga H, Akslen LA. Expression of aldehyde 
dehydrogenase 1 (ALDH1) is associated with basal-like markers and 
features of aggressive tumours in African breast cancer. Br J Cancer. Jan 
19 2010;102(2):369-375. 
 
18. Moitra K, Lou H, Dean M. Multidrug efflux pumps and cancer stem cells: 
insights into multidrug resistance and therapeutic development. Clin 
Pharmacol Ther. Apr 2011;89(4):491-502. 
 
19. Dave B, Chang J. Treatment resistance in stem cells and breast cancer. J 
Mammary Gland Biol Neoplasia. Mar 2009;14(1):79-82. 
 
20. Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast 
cancer cells to chemotherapy. J Natl Cancer Inst. May 7 2008;100(9):672-
679. 
 
21. Campbell LL, Polyak K. Breast tumor heterogeneity: cancer stem cells or 
clonal evolution? Cell cycle. Oct 1 2007;6(19):2332-2338. 
 
 123 
22. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. 
Prospective identification of tumorigenic breast cancer cells. Proc Natl 
Acad Sci U S A. Apr 1 2003;100(7):3983-3988. 
 
23. Perrone G, Gaeta LM, Zagami M, et al. In situ identification of 
CD44+/CD24- cancer cells in primary human breast carcinomas. PLoS 
One. 2012;7(9):e43110. 
 
24. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Aldehyde dehydrogenase 
1-positive cancer stem cells mediate metastasis and poor clinical outcome 
in inflammatory breast cancer. Clin Cancer Res. Jan 1 2010;16(1):45-55. 
 
25. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative 
breast cancer: challenges and opportunities of a heterogeneous disease. 
Nat Rev Clin Oncol. May 17 2016. 
 
26. Stark A, Kleer CG, Martin I, et al. African ancestry and higher prevalence 
of triple-negative breast cancer: findings from an international study. 
Cancer. Nov 1 2010;116(21):4926-4932. 
 
27. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and 
survival in the Carolina Breast Cancer Study. JAMA. Jun 7 
2006;295(21):2492-2502. 
 
28. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma 
characteristics in newly diagnosed African-American and Caucasian 
patients: a single-institution compilation compared with the National 
Cancer Institute's Surveillance, Epidemiology, and End Results database. 
Cancer. Aug 15 2007;110(4):876-884. 
 
29. Stead LA, Lash TL, Sobieraj JE, et al. Triple-negative breast cancers are 
increased in black women regardless of age or body mass index. Breast 
cancer research : BCR. 2009;11(2):R18. 
 
30. Lund MJ, Trivers KF, Porter PL, et al. Race and triple negative threats to 
breast cancer survival: a population-based study in Atlanta, GA. Breast 
cancer research and treatment. Jan 2009;113(2):357-370. 
 
31. McCormack VA, Joffe M, van den Berg E, et al. Breast cancer receptor 
status and stage at diagnosis in over 1,200 consecutive public hospital 
patients in Soweto, South Africa: a case series. Breast cancer research : 
BCR. 2013;15(5):R84. 
 124 
32. Zhang H, Cohen AL, Krishnakumar S, et al. Patient-derived xenografts of 
triple-negative breast cancer reproduce molecular features of patient 
tumors and respond to mTOR inhibition. Breast cancer research : BCR. 
2014;16(2):R36. 
 
33. Zhao X, Liu Z, Yu L, et al. Global gene expression profiling confirms the 
molecular fidelity of primary tumor-based orthotopic xenograft mouse 
models of medulloblastoma. Neuro-oncology. May 2012;14(5):574-583. 
 
34. de Plater L, Lauge A, Guyader C, et al. Establishment and characterisation 
of a new breast cancer xenograft obtained from a woman carrying a 
germline BRCA2 mutation. Br J Cancer. Oct 12 2010;103(8):1192-1200. 
 
35. Evelyn Jiagge JKO, Jessica Bensenhaver, Francis Aitpillah, Kofi Gyan, 
Ishmael Kyei, Ernest Osei-Bonsu, Ernest Adjei, Michael Ohene-Yeboah, 
Kathy Toy, Karen Eubanks Jackson, Marian Akpaloo, Dorcas 
Acheampong, Beatrice Antwi, Faustina Obeng Agyeman, Zainab 
Alhassan, Linda Ahenkorah Fondjo, Osei Owusu-Afriyie, Robert Newman 
Brewer, Amma Gyamfuah, Barbara Salem, Timothy Johnson, Max Wicha, 
Sofia Merajver, Celina Kleer, Judy Pang, Emmanuel Amankwaa-
Frempong, Azadeh Stark, Francis Abantanga, Lisa Newman, Baffour 
Awuah. Breast Cancer and African Ancestry: Lessons Learned at the 10-
Year Anniversary of the Ghana-Michigan Research Partnership and 
International Breast Registry. JOURNAL OF GLOBAL ONCOLOGY. 2016. 
 
36. Ponti D, Costa A, Zaffaroni N, et al. Isolation and in vitro propagation of 
tumorigenic breast cancer cells with stem/progenitor cell properties. 
Cancer research. Jul 1 2005;65(13):5506-5511. 
 
37. Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular 
characterization of the claudin-low intrinsic subtype of breast cancer. 
Breast cancer research : BCR. 2010;12(5):R68. 
 
38. Mendes O, Kim HT, Lungu G, Stoica G. MMP2 role in breast cancer brain 
metastasis development and its regulation by TIMP2 and ERK1/2. Clin Exp 
Metastasis. 2007;24(5):341-351. 
 
39. Chen Q, Boire A, Jin X, et al. Carcinoma-astrocyte gap junctions promote 
brain metastasis by cGAMP transfer. Nature. May 26 2016;533(7604):493-
498. 
40. Li AM, Tian AX, Zhang RX, Ge J, Sun X, Cao XC. Protocadherin-7 induces 




41. Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein-protein 
interaction networks, integrated over the tree of life. Nucleic acids 
research. Jan 2015;43(Database issue):D447-452. 
 
42. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive 
analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-
negative, and HER2-negative invasive breast cancer, the so-called triple-
negative phenotype: a population-based study from the California cancer 
Registry. Cancer. May 1 2007;109(9):1721-1728. 
 
43. Liu S, Cong Y, Wang D, et al. Breast cancer stem cells transition between 
epithelial and mesenchymal states reflective of their normal counterparts. 
Stem Cell Reports. Jan 14 2014;2(1):78-91. 
 
44. Molyneux G, Geyer FC, Magnay FA, et al. BRCA1 basal-like breast 
cancers originate from luminal epithelial progenitors and not from basal 
stem cells. Cell Stem Cell. Sep 3 2010;7(3):403-417. 
 
45. Lim E, Vaillant F, Wu D, et al. Aberrant luminal progenitors as the 
candidate target population for basal tumor development in BRCA1 
mutation carriers. Nat Med. Aug 2009;15(8):907-913 
46. Brooks MD, Burness ML, Wicha MS. Therapeutic Implications of Cellular 
Heterogeneity and Plasticity in Breast Cancer. Cell Stem Cell. Sep 3 
2015;17(3):260-271. 
 
47. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the 
clinic. Nature. Sep 19 2013;501(7467):355-364. 
 
48. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and 
consequences of genetic heterogeneity in cancer evolution. Nature. Sep 
19 2013;501(7467):338-345. 
 
49. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor 
heterogeneity: seeing the wood for the trees. Sci Transl Med. Mar 28 
2012;4(127):127ps110. 
 
50. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and 
branched evolution revealed by multiregion sequencing. N Engl J Med. 
Mar 8 2012;366(10):883-892. 
 
51. Zardavas D, Irrthum A, Swanton C, Piccart M. Clinical management of 
breast cancer heterogeneity. Nat Rev Clin Oncol. Jul 2015;12(7):381-394.
 126 
Chapter 5 : Summary and Discussion 
 
Introduction 
 Overall breast cancer mortality rates decreased by 36% from 1989 to 
2012 in the united states after slowly increasing for many years (0.4% annually 
since 1975)1. As a result of this decline, 249,000 breast cancer deaths have been 
averted in US women from 1990 to 20122. Declines in breast cancer mortality 
rates have been attributed to both improvements in treatment (e.g., adjuvant 
chemotherapy and hormonal therapy in the 1980s and targeted therapies in the 
1990s) and early detection. This means that, if we better understand the biology 
of breast cancer, and thus find the right treatment, stratified to the right patients, 
there is the possibility of saving many lives, not only in the united states but 
globally. 
The gain from recent advancement in treatment however is not evenly 
distributed for all breast cancer patients. Patients with triple negative breast 
cancer still have chemotherapy as the mainstay of treatment since no targeted 
therapy has been successful for this disease. The high proportion of triple 
negative breast cancer in women with African ancestry in the United States likely 
accounts in part for the striking divergence in long-term breast cancer mortality 
trends between black and white women which emerged in the early 1980s and 
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has since continued to widen such that by 2012, mortality rates were 42% higher 
in black women than in white women1,3,4. 
Triple negative breast cancer occur in younger patients, are high grade 
and are the most common breast cancer subtype in patients with BRCA1 
mutation (70 % of breast cancers in patients with BRCA1 mutation are triple 
negative).  
 Globally the highest proportion is in western sub-Saharan Africa 
where single-institution studies reports proportions as high as 80% of all breast 
cancers. Considering the shared ancestry between AA women and women in 
western sub-Saharan African, there is a possibility that African ancestry may be 
associated with a higher chance of developing TNBC. This is further buttressed 
by the similar phenotype of breast cancer in women with African ancestry and 
that in women with hereditary breast cancer. Both groups have early onset breast 
cancer, high grade tumors and higher incidence if male breast cancer. 
 We therefore hypothesized that, the key to understanding the complexity 
of TNBC treatment lies in understanding its biology in women with African 
ancestry in comparison with other ethnicities. 
To validate the hypothesis, I had three aims. The first aim was to create 
patients derived xenografts based on triple negative breast cancer from patients 
in western sub-Saharan Africa, African-American and white patients that will be 
used for experiments. 
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Considering the similarity between breast cancers black women and 
women with hereditary breast cancer (BRCA mutation), our second aim was to 
understand the correlation between African ancestry, triple negative breast 
cancer and BRCAness. BRCAness can be defined as a defect in double-strand 
break repair by homologous recombination5. 
Considering the fact that triple negative breast cancer patients have much 
rapid relapse after chemotherapy with lower survival in the metastatic setting, the 
next aim was to look at the gene expression in the cells that have been shown to 
mediate tumor recurrence, metastasis and resistance to conventional therapy6-11. 
These are the breast cancer stem cells that have also been shown to be 
particularly abundant in triple negative breast cancers, especially that in women 
with African ancestry12,13. 
Below is a summary of the chapters of this thesis, detailing our novel 
approach to understanding the biology of TNBC and thus finding possible new 
drug targets. It reports on our multidisciplinary, international outreach to better 
understand TNBC epidemiology and its impact on patients and care givers in 
chapter II, the possible role of BRCA mutation in chapter III and the importance 




Summary of Chapters 
Chapter 2: The need to create patient derived xenografts from triple 
negative breast cancer patients in western sub-Saharan Africa motivated the 
establishment of a breast cancer research partnership between the Komfo 
Anokye Teaching Hospital in Kumasi, Ghana and the University of Michigan 
Comprehensive Cancer Center in Ann Arbor, Michigan. The aim of this 
collaboration is to better understand the contribution of African ancestry to the 
breast cancer phenotype observed in women with African ancestry, both in Africa 
and in the United States. This aim was pursued by a multidisciplinary 
collaborative partnership between these institution, its staff workers and patients.  
After IRB approval and with informed consent, tissue samples were 
collected from patients receiving treatment for breast cancer. These samples 
were transported to the University of Michigan where they were implanted in 
immunosuppressed mice to create patient derived xenografts models for the 
study of the biology of these tumors. These patient-derived xenografts have been 
used for studying breast cancer stem cells and aggressive triple negative breast 
cancer biology. Tissue samples that were obtained through this collaboration has 
been studied extensively and has led to a better understanding of ethnic/racial 
influences of breast cancer. The benefits of the findings of this work is not only to 
women with African ancestry but to all TNBC patients who desperately need new 
treatments for their disease.  
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The collaborative work led to educational training programs for doctors in 
both institutions as well as scientific investigations related to the comparative 
biology of breast cancer in Ghanaian African, African American, and White 
American patients. In also led to a very significant improvement in the patient 
management protocols in KATH and direct benefits to patients as well.  
Chapter 3: women with mutations in BRCA1 and BRCA2 gene, have 
hereditary susceptibility to breast cancer. Those women with BRCA1 mutation, 
have up to 70% chance of developing TNBC when they develop breast cancer. 
In patients with triple negative breast cancer, there is a 30% chance of harboring 
a mutation in the BRCA compared to 6% in other sporadic breast cancers. 
Women in western sub-Saharan Africa have the highest reported proportion of 
triple negative breast cancer but the prevalence of BRCA mutations or alterations 
in the BRCA associated genes and pathways are not known in these women. We 
first determined the expression of the BRCA1 and BRCA2 protein in formalin 
fixed paraffin embedded samples developed from triple negative breast cancers 
from these women. We discovered that, two thirds of the patient’s sample did not 
express either or both of these tumors. This is the highest report of absence 
expression of BRCA protein indicating that this population might have a high 
prevalence of BRCAness. 
To identify possible causes of the loss expression of the BRCA protein, we 
performed exome sequencing for four of these triple negative breast tumors for 
which we had fresh tumor samples. We identified novel BRCA1 and BRCA2 
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variants in three of the tumors, some of which will likely lead to truncation of the 
protein. This further solidifies the point that this might be a population with a very 
high prevalence of BRCA gene variants or variants in BRCA associated genes 
that leads to impairment in double-strand break repair by homologous 
recombination and so the need for further studies. 
We also compared the characteristics of breast cancer in African-American 
women, white women, and women in western sub-Saharan Africa and in east 
Africa. We confirmed that the frequency of triple negative tumors was highest in 
the Ghanaian patients (50.8%), lowest in the White American and Ethiopian 
patients (15.9% in each), and intermediate in the African Americans (34.3%; 
p=<0.0001). Ghanaian and African-American tumors were more likely to be high 
grade while the Ethiopian tumors had the highest frequency of HER2 over 
expression. It was thus established in this study that significant racial /ethnic 
diversity exists in the breast cancer phenotype. This diversity might contribute to 
the disparity in breast cancer outcomes observed in women of different 
ethnicities. 
 
Chapter 4:  In previous work by our group, we showed a very high 
prevalence of expression of ALDH1, a marker of breast cancer stem cells in 
benign breast tumors in Ghanaian women, even higher expression than was 
observed for malignant tumors in this population. there is ample evidence 
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demonstrating that these breast cancer stem cells are responsible for tumor 
metastasis, resistance to chemotherapy and radiation and for tumor recurrence. 
We therefore sought to identify genes and pathways that are differentially 
expressed between the breast cancer stem cells and the bulk tumor cells in 
primary patient derived xenografts developed from tumors from women with 
divers ethnicities. Using flow cytometry, we sorted for the two populations of 
breast cancer stem cells (CD44+CD24-EPCAM+ and ALDH+) and bulk (live, 
human cells, not excluding stem cells) from 15 (5 Ghanaian, 5 African-American 
and 5 White) patient derived xenografts. We performed RNA sequencing 
(Illumina HiSeq platform) on the isolated populations and bulk cells (45 samples). 
Comprehensive bioinformatics analyses led to the identification of highly 
significantly differentially expressed genes and pathways between the cell 
populations.  By principal component analysis, the tumors were very 
heterogeneous. However, the ALDH+ cells separated out from the CD44+/CD24- 
and the bulk cells. The genes that were significantly differentially expressed in 
the ALDH+ population compared with the other two populations had significant 
signaling interactions using gene ontology.  We identified 14 genes that were 
simultaneously differentially expressed between the ALDH+ vs the CD44+/CD24- 
as well as ALDH+ VS bulk (p-value <0.001, FDR < 0.05). The 3 most significant 
genes were MMP2 and PCDH7, both known to be involved in breast cancer 
metastasis and CPXM1, a carboxylase. The WNT, MAPK and TGF-beta 
pathways known to mediate metastasis were all significantly up-regulated in the 
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ALDH+ population with down regulation of biosynthetic pathways which were up-
regulated in the CD44+/CD24- population. In this study, we identified the ALDH+ 
stem cells to be the only stem cell population in these aggressive breast tumors 
predominantly from women with African ancestry with a significantly higher 





While the research here elucidates some of the biology of triple negative 
breast cancer as it pertains to women with African ancestry, there are so many 
unanswered questions. We demonstrated that, a high percentage of breast 
tumors from Ghanaian patients had loss of expression of BRCA proteins and 
three out of four of these patients whose tumors were sequenced had variants in 
the BRCA gene. However, we have not been able to validate that the loss of 
BRCA protein as observed in the immunohistochemistry staining is due to 
mutation in the BRCA gene.  It will be important therefore to investigate the 
BRCA1 mutation frequency in African women with TNBC as well as down-
regulation of BRCA1 expression by other non-genetic means, both of which are 
speculated to be very high. 
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 Using PDXs, we are the first to create a renewable tumor resource 
from women with native African ancestry (Ghanaian) and establish a comparative 
gene profiling system between the BCSC of ethnically diverse tumors. This study 
represents about the only study of the biology of TNBC and stem cells in which 
two thirds of the sample population is of women with African ancestry with half of 
them being from women with pure African ancestry. The sample size used for 
this experiment was not large enough to determine an ethnic relationship with the 
gene and pathway expression. There is therefore the need to increase the 
sample size to determine if there are genes and pathways that are differentially 
expressed in triple negative breast cancer in women with African ancestry that 
can be targeted for therapy. 
Our data infers that ALHD as a marker of breast cancer stem cells may 
represent an interesting link into the biology of the TNBC tumors. We have, 
shown that matrix metalloproteases are highly upregulated in ALDH expressing 
breast cancer stem cells. Several studies have shown that MMPs play an 
important role in tumor metastasis by degrading extracellular matrix. But the 
therapies directed against MMPs have not been effective in the clinic. In our 
studies, we have shown that MMP-2 is highly expressed and maintained in in 
vivo system in the breast cancer stem cells. Our data suggests that the 
disconnect in the preclinical studies and the clinical data may partly be due to 
inadequate model system used to study the potential role of MMPs as a target. 
Our studies impress upon the role of MMPs in connection to breast cancer stem 
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cell. It will be interesting to further study the role of MMP and ALDH-1 in relation 
to breast cancer stem cells. Apart from MMP we have identified several other 
genes that were significantly up-regulated in the ALDH expressing stem cells. 
These include CPXM1, a carboxylase whose function is yet to be determined14 
and PCDH7 which has been shown to induce metastasis in breast cancer15. 
Focusing on targeting the genes and pathways we discovered in this study has 
the potential to lead to therapies that may be effective across ethnicities, thereby 





Triple negative breast cancer is a very heterogeneous disease making it 
extremely difficult to target. Previous attempts to find targeted therapy for this 
disease has failed thus the need to find different approaches to understand its 
biology and find new drug targets is urgently needed. In this study, we chose a 
novel approach by studying the population with the highest proportion of the 
disease (African women) and the cells that most likely mediate the tumors 
aggressive phenotype (breast cancer stem cells). Here we have Studied the 
biology of breast cancer stem cells in actual patient tumors which has provided 
further insight into novel genes and pathways that may be potential drug targets 
in this disease. Targeting these genes and pathways may have the potential of 
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benefiting black women with triple negative breast cancer who have been 
underrepresented in previous research and clinical trials. It will also benefit all 
patient with triple negative breast cancer irrespective of their racial/ethnic 





1. Howlader N NA, Krapcho M, et al. . SEER Cancer Statistics Review, 1975-
2012, based on Nov 2014 SEER data submission. Bethesda, MD: National 
Cancer Institute;. 2015. 
 
2. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal 
A. Breast cancer statistics, 2015: Convergence of incidence rates between 
black and white women. CA Cancer J Clin. 2016;66(1):31-42. 
 
3. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant 
therapy on mortality from breast cancer. N Engl J Med. 
2005;353(17):1784-1792. 
 
4. Munoz D, Near AM, van Ravesteyn NT, et al. Effects of screening and 
systemic adjuvant therapy on ER-specific US breast cancer mortality. J 
Natl Cancer Inst. 2014;106(11). 
 
5. Lord CJ, Ashworth A. BRCAness revisited. Nature reviews Cancer. 
2016;16(2):110-120. 
 
6. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern 
of metastatic spread in triple-negative breast cancer. Breast cancer 
research and treatment. 2009;115(2):423-428. 
 
7. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy 
and long-term survival in patients with triple-negative breast cancer. J Clin 
Oncol. 2008;26(8):1275-1281. 
 
8. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: 
clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 
Pt 1):4429-4434. 
 
9. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary 
tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 
2007;13(8):2329-2334. 
 
10. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Aldehyde dehydrogenase 
1-positive cancer stem cells mediate metastasis and poor clinical outcome 
in inflammatory breast cancer. Clin Cancer Res. 2010;16(1):45-55. 
 
 138 
11. Dontu G, Abdallah WM, Foley JM, et al. In vitro propagation and 
transcriptional profiling of human mammary stem/progenitor cells. Genes 
Dev. 2003;17(10):1253-1270. 
 
12. Nalwoga H, Arnes JB, Wabinga H, Akslen LA. Expression of aldehyde 
dehydrogenase 1 (ALDH1) is associated with basal-like markers and 
features of aggressive tumours in African breast cancer. Br J Cancer. 
2010;102(2):369-375. 
 
13. Schwartz T, Stark A, Pang J, et al. Expression of aldehyde dehydrogenase 
1 as a marker of mammary stem cells in benign and malignant breast 
lesions of Ghanaian women. Cancer. 2013;119(3):488-494. 
 
14. Ota T, Suzuki Y, Nishikawa T, et al. Complete sequencing and 
characterization of 21,243 full-length human cDNAs. Nat Genet. 
2004;36(1):40-45. 
 
15. Li AM, Tian AX, Zhang RX, Ge J, Sun X, Cao XC. Protocadherin-7 induces 
bone metastasis of breast cancer. Biochem Biophys Res Commun. 
2013;436(3):486-490. 
 
